[COMPANY_001] Confidential Page [ADDRESS_1134901] of abbreviations ............................................................................................................ 7
Glossary  of terms ............................................................................................................... 10
Amendment 2  (04 Jun 2020) ................................................................................................... 11
Amendment 1 (April 2017) ...................................................................................................... 11
Protocol summary .............................................................................................................. 13
1Introduction ....................................................................................................................... 17
1.1 Background ............................................................................................................ 17
1.2 Purpose .................................................................................................................. 19
2Study  objectives and endpoints ......................................................................................... 19
2.1 Primary  objective(s) ............................................................................................... 19
2.2 Secondary  objective(s) ........................................................................................... 19
19
2.4 Objectives and related endpoints ........................................................................... 20
3Investigational plan ........................................................................................................... 23
3.1 Study  design ........................................................................................................... 23
3.2 Rationale for stud y design ..................................................................................... 25
3.3
Rationale for dose/regimen, route of administration and duration of treatment ....26
3.4 Rationale for choice of comparator ....................................................................... 28
3.5 Purpose and timing of interim anal yses/design adaptati ons
.................................. [ADDRESS_1134902] -study  treatment .......................................... 44
5.6.2 Discontinuation of study  treatment ....................................................... 44
5.6.3 Withdrawal of informed consent ........................................................... 45
5.6.4 Loss to follow -
up .................................................................................. 46
5.6.5 Early study termination by [CONTACT_456] ................................................. 46
6
Visit schedule and assessments ......................................................................................... 46
6.1 Information to be collected on screening failures .................................................. 56
6.2 Patient demographics/other baseline characteristics ............................................. 56
6.3 Treatment 
exposure and compliance ..................................................................... 56
6.4 Efficacy .................................................................................................................. 56
6.4.1 JIA ACR response criteria .................................................................... 57
6.4.2 Physician’s Global Assessment of disease activity  (VAS) ................... 58
6.4.3 Parent’s/patient’s Global Assessment of subject’s overall well
-
being (VAS) .......................................................................................... 58
6.4.4 Childhood Health Assessment Questionnaire (CHAQCopyright)
............. 58
6.4.5 Active joint count .................................................................................. 58
6.4.6
Joint counts with limitation of motion .................................................. 59
6.4.7
C-reactive Protein (CRP) ...................................................................... [ADDRESS_1134903] ylitis count ............................................................................. 60
6.4.12 Total enthesitis count ............................................................................ 60
61
61
61
61

[COMPANY_001] Confidential Page 4
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
62
62
63
6.4.20 Juvenile Arthritis Disease Activity  Score (JADAS) ............................. [ADDRESS_1134904] ...................................... 65
6.5.5 Laboratory  evaluations .......................................................................... 66
6.5.6 Electrocardiogram (ECG) ..................................................................... 67
6.5.7 Pregnancy  and assessments of fertility ................................................. 67
6.5.8 Tolerability
 of secukinumab ................................................................. 68
6.5.9 Immunogenicit y
.................................................................................... 68
6.5.10 Appropriateness of safety  measurements .............................................. 69
6.6 Other assessments .................................................................................................. 69
6.6.1 Resource utilization ............................................................................... 69
6.6.2 Pharmacokinetics .................................................................................. 69
71
71
7Safety  monitoring .............................................................................................................. 72
7.1 Adverse events ....................................................................................................... 72
7.2 Serious adverse events ........................................................................................... 73
7.2.1 Definition of SAE ................................................................................. 73
7.2.2 SAE reporting
........................................................................................ 74
7.3 Liver safety  monitoring ......................................................................................... 75
7.4 Renal safet y monitoring ......................................................................................... 76
7.5 Reporting of stud y treatment errors including misuse/abuse ................................ 76
7.6 Pregnancy  reporting ............................................................................................... 77
8Data review and database management ............................................................................. 77
8.1 Site monitoring ...................................................................................................... 77
8.2
Data collection....................................................................................................... 78

[COMPANY_001] Confidential Page 5
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
8.3 Database management and quality  control ................................ ............................ 78
8.4 Data Monitoring Committee .................................................................................. 79
8.5 Adjudication Committee ........................................................................................ 79
9Data analy sis...................................................................................................................... 80
9.1 Analy sis sets .......................................................................................................... 80
9.2
Patient demographics and other baseline characteristics....................................... 81
9.3 Treatments ............................................................................................................. 81
9.4 Analy sis of the primary  variable(s) ....................................................................... 81
9.4.1 Variable(s) ............................................................................................. 81
9.4.2 Efficacy  variables
.................................................................................. 82
83
9.4.4 Safety
 variables ..................................................................................... 84
9.5 Interim anal yses..................................................................................................... 85
9.6
Sample size calculation.......................................................................................... 85
10Ethical considerations ................................ ................................ ................................ ........ 86
10.1 Regulatory and ethical compliance ........................................................................ 86
10.2 Informed consent procedures
................................................................................. 86
10.3 Responsibilities of the I nvestigator and IRB/ IEC................................................. 87
10.4 Publication of study  protocol and results ............................................................... 87
11Protocol adherence ................................ ................................ ................................ ............ 87
11.1 Protocol Amendments ........................................................................................... 88
12References (available upon request) ................................ ................................ .................. 89
13Appendix 1: Clinically  notable laboratory  values and vital signs ..................................... 91
14Appendix 2: L iver event and Laboratory  trigger Definitions and Follow
-up 
Requirements ..................................................................................................................... 95
15Appendix 3: Specific Renal Alert Criteria and Actions .................................................... 98
16Appendix 4: Weight ranges: recommended maximum sample blood volume per 
blood draw ......................................................................................................................... 99
17Appendix 5: Phy sician’s global assessment of disease activit y (VAS) ............................ 99
18
Appendix 6: Childhood Health Assessment Questionnaire (CHAQ) ............................. 100
19 Appendix 7: ILAR classification criteria ................................ ................................ ........ 102
20Appendix 8: ACR d efinition of flare for J IA.................................................................. 103
21Appendix 9: ACR response criteria ................................................................................. 104
22
Appendix 10: Criteria for de ﬁning clinical inactive disease ........................................... [ADDRESS_1134905] of tables
Table 2-1 Objectives and related endpoints .......................................................... 20
Table 5
-1 Prohibited medication ........................................................................... 41
Table 6
-1 Assessment schedule ............................................................................. 49
62
63
Table 6
-4 IG sample log ........................................................................................ 69
Table 6
-5 PK sample log ....................................................................................... 70
71
71
Table 7
-1 Treatment Errors ................................................................................... 77
Table 13
-1 Reference ranges for s ystolic and diastolic blood pressures and 
pulse. ..................................................................................................... 93
Table 13
-2 Recomm ended dimensions for blood pressure cuff bladders ............... 94
Table 14-1 Liver Event and Laboratory  Trigger Definitions .................................. 95
Table 14
-2 Follow Up Requirements for L iver Events and Laboratory  Triggers ...95
Table 15-1 Specific Renal Alert Criteria and Actions ............................................. 98
Table 16
-1 Weight range: Recommended maximum blood volume drawn per 
visit, and per [ADDRESS_1134906] of figures
Figure 3-1 Study  design .......................................................................................... 25
Figure 3 -
2 2000 CDC growth chart (median weight and 5 to 95% range)............. 27
Figure 3-3 Simulated values for average concentration over the dosing interval
(Cavg) b y weight based on RA patients ................................................ [ADDRESS_1134907] Bioanalytical data report
BP Blood pressure
Cavg Average concentration 
CDC Center for Disease Control and Prevention
CDER Center for Drug Evaluation and Research
CFR US Code of Federal Regulations 
CHAQ Childhood Health Assessment Questionnaire
CONSORT Consolidated Standards of Reporting Trials
CRF Case Report/Record Form (paper or electronic)
CPO Countr y Pharma Organization
CRO Contract Research Organization
CRP C-reactive Protein
CS Corticosteroid
CTCAE Common Terminology Criteria for Adverse Events
DAR Dose Administration Record
DDE Direct data e ntry
DMARD Disease modifying anti -rheumatic drug
DMC Data Monitoring Committee
ECG Electrocardiogram
eCRF Electronic Case Report/Record Form
EDC Electronic Data Capture
ELISA Enzy me-linked immunosorbent assay
EMA European Medicine Agency
ERA Enthesitis -Related Arthritis
 
FAS Full analy sis set
GCP Good Clinical Practice
GGTGamma -glutam yl transferase
hCG Human Chorionic Gonadotropin

[COMPANY_001] Confidential Page [ADDRESS_1134908] ug
OC/RDC Oracle Clinical/Remote Data Capture
PCR Polymerase chain reaction
PFS Prefilled Sy ringe
PK Pharmacokinetics
[COMPANY_003] Purified protein derivative
PsA Psoriatic Arthritis
PRO Patient Reported Outcome
PRN As required
PSW Premature subject withdrawal
PUVA Photochemotherapy
QTcF QTc Interval by [CONTACT_6550]’s equation

[COMPANY_001] Confidential Page [ADDRESS_1134909]
RF Rheumatoid Factor
RU Healthcare Resource Utilization
SAE Serious Adverse Event
s.c. Subcutaneous
sCr Serum creatinine
SGOT Serum glutaminc oxaloacetic transaminase
SGPT Serum glutamic -pyruvic transaminase
SI Sacroiliac (joint)
SJC Swollen Joint Count
SNP Single Nucleotide Poly morphism
SpA Spondyloarthropathy (or spondy loarthritis)
SSZ Sulfasalazine
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reactions
TB Tuberculosis
TBL Serum total bilirubin
TD Study Treatment Discontinuation
tid Twice daily
TJC Tender Joint Count
TNF Tumor Necrosis Factor
Tx Treatment
ULN Upper limit of normal
[LOCATION_006] [LOCATION_008]
US [LOCATION_002]
UV Ultraviolet
VAS Visual Analogue Score
WBC White blood cell
WHO World Health Organization 
WoC Withdrawal of Consent

[COMPANY_001] Confidential Page 10
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
Glossary  of terms
Cohort A specific group of patients/subjects fulfilling certain criteria
Control drug Drugs(s) used as a comparator to reduce assessment bias, preserve 
blinding of investigational drug, assess internal study validity, and/or 
evaluate comparative effects of the investigational drug
Dosage Dose of the study treatment given to the patient in a time unit (e.g. 100 
mg once a day, 75 mg twice a day)
Electronic Data Capture 
(EDC)Electronic data capture (EDC) is the electronic acquisition of clinical study 
data using data collection systems, such as Web-based applications, 
interactive voice response sy stems and clinical laboratory interfaces.
EDC includes the use of Electronic Case Report Forms (eCRFs) which 
are used to capture data transcribed from paper source forms used at the 
point of care.
Enrollment Point/time of patient entry into the study at which informed consent must 
be obtained (e.g. prior to starting any of the procedures described in the 
protocol)
Study Period A portion of the study which serves a specific purpose. T ypi[INVESTIGATOR_819415]: screening/recruitment, wash -out, treatment, and follow -up
Investigational drug The drug whose properties are being tested in the study; this definition is 
consistent with US Code of Federal Regulations (CFR) 21 Section 312.3 
and is synony mous with “i nvestigational new drug” or “investigational 
medicinal product.”
Medication pack number A unique identifier on the label of each investigational drug package
Part A single component of a study which contains different objectives or 
populations within that single study. Common parts within a study are: a 
single dose part and a multiple dose part, or a part in patients/subjects 
with established disease and in those with newly -diagnosed disease.
Patient/subject ID A unique number assigned to each patien t upon signing the informed 
consent 
Randomization number A unique identifier assigned to each randomized patient, corresponding to 
a specific treatment arm assignment
Source Data/Document Source data refers to the initial record, document, or primary  location from 
where data comes. The data source can be a database, a dataset, a 
spreadsheet or even hard -coded data, such as paper .
Study drug/ treatment Any single drug or combination of drugs administered to the patient as 
part of the required study procedures; includes investigational drug (s), 
placebo/comparator active drug run -ins or background therapy
Study Treatment 
Discontinuation (TD)When the patient permanently stops taking study treatment prior to the 
defined study treatment completion date
Variable A measured value or assessed response that is determined in specific 
assessments and used in data analysis to evaluate the drug being tested 
in the study
Withdrawal of consent 
(WoC)Withdrawal of consent from the study is defined as when a patient does 
not want to participate in the study any longer, and does not want any 
further visits or assessments, and does not want any further study related 
contact, and does not allow analysis of already obtained biologic material

[COMPANY_001] Confidential Page 11
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
Amendment 2 (04Jun 2020)
Amendment rationale 
The reason for this amendment is to adapt the protocol to COVID 19 pandemic/epi[INVESTIGATOR_819416].   
Section 5.5.2 is updated to include text allowing for shipment ofIMP to the patient’s home 
during a major health care disruption (e.g., COVID 19 pandemic/epi[INVESTIGATOR_901]) .Section 5.5.[ADDRESS_1134910] fo
r patients 
where IMP is shipped to the patient’s home and how to report the home administration. 
Additional clarifications for instances where the IMP is shipped to the patient’s home are 
added to Section [ADDRESS_1134911] been updated or corrected as well to further optimize the clinical trial 
protocol. 
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
This amended protocol is considered non-substantial as it includes measures in 
response/relation to the pandemic/epi[INVESTIGATOR_819417] 19 situation and will not be submitted to 
IRB/IEC approval prior to implementation in line with the guidance from multiple health 
authorities worldwide.
The changes herein does not affect the main Global Model Informed Consent.  Sites are 
required to submit for approval anadditional Informed Consent that takes into account 
delivery  of IMP directly  to a participant’s home and home administration.
Summary  of previous amendments 
Amendment 1 (April 2017)
Amendment rationale
At the time of this amendment no subjects have 
been randomized in the study . No change to 
the study  population is proposed by  [CONTACT_819427]:
1. To clarify  and correct errors in the ILAR diagnostic c riteria detailed in Appendix 7 .  

[COMPANY_001] Confidential Page 13
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
Protocol summary
Protocol number CAIN457F2304
Title A three -part randomized, double -blind, placebo -controlled study to 
investigate the efficacy  and safety of secukinumab treatment in Juvenile 
Idiopathic arthritis subtypes of psoriatic and enthesitis -related arthritis 
Brief title Secukinumab safety and efficacy  in JPsA and ERA
Sponsor and Clinical 
Phase[COMPANY_001] Pharma AG
Investigation type Drug
Study type Interventional
Purpose and 
rationaleThe purpose of this study is to demonstrate the efficacy and safety of 
secukinumab treatment in children ≥ 2 to <18 years of age with active ERA
(Enthesitis- Related Arthritis) and JPsA (Juvenile Psoriatic Arthritis) 
categories of JIA (Juvenile Idiopathic Arthritis) and to demonstrate the 
sustained efficacy of secukinumab by [CONTACT_2329] a flare prevention design in a 
double -blind placebo control treatment withdrawal part of the trial. 
Additionally, this study will evaluate predicted pediatric doses to achieve 
secukinumab level equivalency of adult 150 mg dosing
Primary Objective(s) To demonstrate that the time to flar e in Treatment Period [ADDRESS_1134912] of secukinumab treatment for all patients and 
each JIA category in Treatment Period 1 up to Week 12 (end of 
Treatment period 1) with respect to :
JIA ACR (American College of Rheumatology ) 30/50/70/90/100 and 
inactive disease status 
Each JIA ACR core component 
Change from baseline Juvenile Arthritis Disease Activity Score 
(JADAS) 
Total enthesitis count
Total dacty litis count
2.To evaluate withdrawal effect of secukinumab treatment for all patients 
and each JIA category during and at the end of Treatment Period [ADDRESS_1134913] to:
JIA ACR 30/50/70/90/100 and inactive disease status 
3.To evaluate Pharmacokinetics (PK) of secukinumab and confirm the 
predicted dose in Treatment Period 1 
4.To evaluate the safety/tolerability and immunogenicity of Secukinumab
Study design This is a double -blind, placebo -controlled, event -driven randomized 
withdrawal study to investigate the efficacy and safety of secukinumab 
treatment in the JIA categories of JPsA and ERA. The study is divided into 3 
parts (plus a post -treatment follow -up period) consisting of open- label, 
single -arm active treatment in Treatment Periods 1 and 3 and a rand omized, 
double -blind, placebo controlled, event -driven withdrawal design in 
Treatment Period 2 .
Population Male and female patients aged from ≥ 2 years to < 18 years who are 
diagnosed with either enthesitis -related arthritis (ERA) based on fulfilling the 
ILAR (International League of Associations for Rheumatology) JIA 

[COMPANY_001] Confidential Page 14
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
classification criteria or JPsA based on fulfilling a modified ILAR JIA 
classification criteria and who are naïve to biologic treatments .
Key Inclusion criteria 1.Males and females ≥2 years o ld and < [ADDRESS_1134914] 6 months prior to Screening.
3.Active dis ease (ERA or JPsA) defined as having both: 
≥ 3 active joints (swollen or if not swollen must be both tender and 
limited range of motion) at Baseline.
≥1 site of active enthesitis at Baseline or documented by [CONTACT_969] 
4.Inadequate response ( ≥ 1 month) or int olerance to ≥ 1 NSAID (Non -
Steroidal Anti -inflammatory Drug) 
5.Inadequate response ( ≥ 2 months) or intolerance to ≥ [ADDRESS_1134915] (Disease 
Modifying Anti -rheumatic Drugs)
6.No concomitant use of second line agents such as disease- modifying 
and/or immunosuppressive drugs will be allowed with the exception of 
the following agents which must remain at stable dose during trial 
Treatment Periods 1 and 2.
Stable dose of methotrexate (maximum of 20 mg/ m2BSA (body 
surface area)/ week) for at least 4 weeks prior to the bas eline visit, 
and folic/folinic acid supplementation (according to standard medical 
practice of the center)
Stable dose of SSZ ( Sulfasalazine ) (ERA patients only) < 50 
mg/kg/day with max of 3000 mg/day for at least 4 weeks prior to the 
baseline visit
Stable dose of an oral corticosteroid (CS) at a prednisone equivalent 
dose of < 0.2 mg/kg/day or up to 10 mg/day maximum, whichever is 
less, for at least 7 day s prior to baseline
Stable dose of no more than [ADDRESS_1134916] 1 week prior to 
baseline
7.Negative QuantiFERON (QF) test. Negative Purified Protein Derivative 
([COMPANY_003]) test is also acceptable if either required by [CONTACT_819428] < 5 years of age. A positive [COMPANY_003] is defined as > 15mm 
induration for children > 4 years and > 10mm for children < [ADDRESS_1134917] ever received biologic immunomodulating agents , 
including but not limited to TNFα (Tum or Necrosis Factor alpha) 
inhibitors, T -cell costimulatory, Anti -IL6(interle ukin) , Anti -IL1, cell-
depleting therapi[INVESTIGATOR_90156] -CD20 (e.g., 
alem tuzum ab, anti -CD4, anti -CD5, anti -CD3, and anti -CD19), 
secukinumab or other biologic drugs directly targeting IL -[ADDRESS_1134918] except for MTX (Methotrexate) 
(or sulfasalazine [SSZ] for ERA patients only ).
5.Patients fulfilling any ILAR diagnostic JIA categor y other than ERA or 
JPsA.

[COMPANY_001] Confidential Page 15
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
6.Patients taking medications prohibited by [CONTACT_760] .
7.Any intram uscular/intravenous/intra- articular corticosteroid treatment 
within 4 weeks before baseline.
8.Active or recurrent bacterial, fungal or viral infection including known 
infection with Human Immunodeficiency Virus (HIV), Hepatitis B, and 
Hepatitis C at baseline.
9.History or evidence of active tuberculosis (TB) or evidence of Latent TB 
(positive QuantiFERON or [COMPANY_003] at screening) but unwilling or unable to 
complete a minimum of 4 weeks of latent TB treatment before initiating 
treatment with se cukinumab. 
10.Pregnant or nursing (lactating) females, where pregnancy is defined as 
the state of a female after conception and until the termination of 
gestation, confirmed by a positive hCG (human chorionic gonadotropin) 
laborator y test.
11.Female patients (< 18 years of age) of childbearing potential (menarchal 
or becoming menarchal during the study ) who do not agree to 
abstinence or, if sexually active, do not agree to the use of contraception 
as defined in the protocol.
Study treatment Investigational trea tment
Secukinumab 150mg/1mL, liquid formulation provided in 1 mL PFS 
(Pre-filled syringe)
Secukinumab 75mg/0.5mL, liquid formulation provided in 0.5 mL 
PFS 
Reference treatment
Placebo, liquid formulation in a 1 mL and 0.5 mL PFS
Efficacy 
assessmentsJIA ACR 30, 50, 70, 90 and 100 response criteria
Physician’s Global Assessment of disease activity (VAS) (Visual 
Analogue Score)
Parent’s/patient’s Global Assessment of subject’s overall well -being (VAS 
included within CHAQ©)
Childhood Health Assessment Questi onnaire (CHAQ©)
Active joint count
Joint count with limited range of motion
CRP (C -Reactive Protein) (local)
Inactive disease status
 
 
JADAS score
Total dactylitis count
Total enthesitis count
 

[COMPANY_001] Confidential Page 16
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
Key safety 
assessmentsAdverse events/serious adverse events (AE/SAE)
Electrocardiogram (ECG)
Laboratory evaluations
Immunogenicity
Other assessments Secukinumab levels
Data analysis The primary  objective for Treatment Period 2 of the study is to show 
superiority of Secukinumab over placebo regarding the primary  variable in 
Treatment Period 2.
The following statistical hypothesis will be tested once the required number 
of flares has been observed and the study has been stopped:
H0: 1 -SA N(t) ≥ 1- SPla(t) 
HA: 1 -SA N(t) < 1 - SPla(t)
at each time point t, with S AIN(t) and S Pla(t) being the survivor functions in the 
Secukinumab and placebo treatment group at time t.
The two treatment groups will be compared using a one- sided stratified 
Logrank test with the stratification factor of JIA category (ERA or JPsA) at 
the 2.5% level of significance. Hazard ratios and th eir associated 95% 
confidence intervals will be estimated based on a Cox proportional hazards 
model with treatment and stratification factor as explanatory variables.
Safety analy ses will include summaries of AEs, laboratory measurements, 
and vital signs.
Key words JIA, JPsA, ERA, Secukinumab, ILAR

[COMPANY_001] Confidential Page 17
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
1 Introduction
1.1 Background 
Juvenile idiopathic arthritis (JIA) represents a heterogeneous group of chronic idiopathic 
arthritides of at least [ADDRESS_1134919] variable clinical presentations and prognoses, variable age of onset, 
and are a major cause of morbidity . The reported prevalence and incidence of JIA varies 
widely . The prevalence in Europe ranges from 0.2 to 2.0 per 1000 children, and in the US 
([LOCATION_002]), the prevalence has been reported to be approximately  0.45 per 1000 children.  
The International League of Associations for Rheumatology  (ILAR) classification criteria 
(Petty et al 2004) identify  the following seven JIA categories characterized by [CONTACT_819429]: 
Polyarticular ( Rheumatoid Factor (RF) positive); 
Polyarticular (RF negative); 
Oligoarticular; 
Juvenile psoriatic Arthritis (JPsA); 
Enthesitis
-related Arthritis (ERA) and;
Systemic
Undifferentiated
Of the seven JIA categories, Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related 
Arthritis (ERA) represent a spondy loarthropathy  (SpA) similar to the adult 
spondy loarthropathies of psoriatic arthritis ( PsA) and ankylosing spondy litis (AS) 
respectivel y.
Juvenile psoriatic arthritis (JPsA) is an inflammatory  arthritis which can present with or 
without psoriasis skin involvement and accounts for approximately  5 to 10% of the total JIA 
population. The curre nt ILAR classification criteria for JPsA include two distinct groups of 
patients; one clinically  similar to JIA oligoarthritis and the other clinicall y similar to the adult 
spondy loarthritis condition of PsA ( Horn eff 2009, Martini 2003, Martini 2012 ). Those with an 
oligoarthritis
-like condition usually  present at a young age (2 to 4 years old) with asymmetric 
oligoarthritis, are at risk for the development of iridocy clitis, and are frequentl y ANA 
(Antinuclear antibodies) positive. Those with a more adult PsA-like condition usually  present 
at a later age (> 6 -9 years old) with a lower extremity  arthritis, enthesitis and, in a minor ity of 
patients, axial involvement, and are often HLA -B27 positive. (Human Leukocy te Antigen)
Enthesitis- related arthritis (ERA) is a clinicall y heterogeneous group including some who 
have predominantly  enthesitis, enthesitis and arthritis, juvenile ankylosing spondy litis, or 
inflammatory  bowel disease -
associated (IBD) arthropathy . ERA accounts for approximately 
3%–11% of J IA. 
ERA has a strong genetic predisposition as evidenced by a positive family  history  and the 
high frequency  of the presence of HLA -B27 in affected patients. The hallmarks of the disease 
are pain, stiffness, and eventual loss of mobility  of the back, similar to adult ankylosing 

[COMPANY_001] Confidential Page 18
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
spondy litis. ERA should be suspected in any child with chronic arthritis of the axial and 
peripheral skeleton, enthesitis (inflammation at points where tendons insert to bone), and 
Rheumatoid Factor (RF) and Anti -nuclear antibody  (ANA) seronegativity . Peripheral arthritis, 
also similar to adult AS, usually  affecting few joints of the lower extremity , precedes axial 
involvement, and arthritis of the sacroiliac joints may take years to develop.  Unlike adults 
with AS, the arthritis in children with ERA can be very aggressive and lead to hip 
replacement more often than in adult AS patients. Radiographic changes of the s acroiliac joint 
include joint space narrowing, erosions, sclerosis, osteoporosis of the pelvis, and fusion (a late 
finding).
In 2011, the American College of Rheumatology  (ACR) established JIA treatment guidelines 
which are applicable to all JI A categories, including the spondy loarthropathies JPsA and ERA 
(Beuckelman et al 2011 ).The guidelines aim to quickly  control active inflammation and 
patient symptoms and to prevent/minimize disease and/or treatment -related m orbidities (e.g. 
growth disturbances, joint damage, and functional limitations).    In general, the treatment 
goal is to target controlling the inflammation with NSAI Ds (Non -steroidal anti-inflammatory 
drugs), corticosteroids as intraarticular injections, DMARDs (Disease modify ing anti-
rheumatic drugs) and biologic agents either as monotherap y or in combination with other 
therapi[INVESTIGATOR_014] (DMARD and/or NSAI D).  Successful management requires careful long-term 
monitoring of disease activity  and willingness to adjust treatments as necessary  to achieve and 
maintain the lowest level of disease activity .
Secukinumab (AIN457) is a high-affinit y fully human monoclonal anti-human antibody  that 
targets IL-17A and neutralizes activity .  Secukinumab treatment has demonstrated significant 
and clinicall y meaningful efficacy  in treating adults with anky losing spondy litis (AS) and 
psoriatic arthritis (PsA), both approved indications. 
Theadult AS and PsA secukinumab data support the proposed secukinumab study  in children 
with sim ilar pediatric spondy loarthritic conditions: ERA and JPsA. This study  will investigate 
secukinumab treatment in children ≥ 2 to < 18 years of age with active JPsA or ERA JIA 
using a pediatric dose equivalent to the adult 150mg dose.  To ensure children with a more 
SpA-like condition ( Martini 2012 ) are not excluded, the ILAR diagnostic criteria for JPsA are 
modified NOT to exclude those who are:
HLA –B27 - positive male beginning after the 6thbirthday ; 
those who have AS, ERA, sacroiliitis with Inflammatory  Bowel Disease (IBD), reactive 
arthritis (Reiter’s s yndrome) , or acute anterior uveitis, or a history  of one of these 
disorders in a first -degree relative.
This 2-year study  consists of [ADDRESS_1134920]-treatment follow - up period: The initial 
Treatment Period [ADDRESS_1134921] 4 weeks (loading dose period) and at Week 8. Responders (minimum JIA 
ACR30 response) at the end of Treatment Period 1 (Week 12) will enter into Treatment 
Period 2 and be randomized 1:[ADDRESS_1134922]-treatment follow -up period.  Treatment 
Period 2 will continue until 33 patients experience a disease flare (as per American College of 
Rheumatology  (ACR) flare definition). Patients ex periencing a flare and those who remain (in 

[COMPANY_001] Confidential Page 19
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
Treatment Period 1 or 2) when Treatment Period [ADDRESS_1134923] study  treatment administration for all patients unless the patient enters the extension 
trial.  
All patients who successfully  complete the study  (104 weeks) will be eligible to continue 
secukinumab treatment in an extension trial.  
1.2 Purpose 
The purpose of this study  is to demonstrate the efficacy  and safet y of secukinumab treatment 
in children ≥2 to <18 years of age with active ERA and JPsA categories of JIA and to 
demonstrate thesustained efficacy  of secukinumab by [CONTACT_2329] a flare prevention design in a 
double -blind placebo control treatment withdrawal part of the trial. Additionally , this study  
will evaluate predicted pediatric doses to achieve secukinumab level equivalency  of adult 
150mg dosing. 
2 Study  objectives and endpoints
2.1 Primary  objective(s)
To demonstrate that the time to flare in Treatment Period 2 is longer with secukinumab for 
combined ERA and JPsA groups than with placebo.
2.2 Secondary  objective(s)
1.To evaluate effect of secukinumab treatment for all patients and each J IA category  in 
Treatment Period 1 up to Week 12 (end of Treatment period 1) with respect to:
JIA ACR 30/50/70/90/100 and inactive disease status 
Each J IA ACR core component 
Change from baseline Juvenile Ar thritis Disease Activity  Score (JADAS) 
Total enthesitis count
Total dact ylitis count
2. To evaluate withdrawal effect of secukinumab treatment for all patients and each J IA 
category  during and at the end of Treatment Period [ADDRESS_1134924] to:
JIA ACR 30/50/70/90/100 and inactive disease status 
3. To evaluate Pharmacokinetics (PK) of secukinumab and confirm the predicted dose in 
Treatment Period 1 
4.To evaluate the safet y/tolerability  and immunogenicity  of Secukinumab

[COMPANY_001] Confidential Page 20
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
2.4 Objectives and related endpoints
Table 2-1 Objectives and related endpoints
OBJECTIVE Endpoint Title, Description and 
Reporting Time Frame for 
analysis and Unit of MeasureStat 
AnalysisSection
Primary
To demonstrate that the time to flare in  
Treatment Period 2 is longer with 
secukinumab for combined ERA and 
JPsA groups than with placeboTime to disease flare (active vs. 
control). Flare definition (see 
Appendix 8 )Section 9.4.1
Timeframe: Treatment Period [ADDRESS_1134925] of 
secukinumab treatment for all 
patients and each JIA category in 
Treatment Period 1 up to W eek 12 Section 9.4.2

[COMPANY_001] Confidential Page 21
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
(end of Treatment Period 1) with 
respect to:
JIA ACR 30/50/70/90/100 and 
inactive disease status JIA ACR 30/50/70/90/100 (s ee 
Appendix 9 )
inactive disease status
Each JIA ACR core component JIA ACR core components
Change from baseline JADAS 
scoreJADAS score
Total enthesitis count Total enthesitis count
Total dactylitis count Total dactylitis count
Timeframe: Treatment Period [ADDRESS_1134926] to:
JIA ACR 30/50/70/90/100 and 
inactive disease status JIA ACR 30/50/70/90/100 (s ee 
Appendix 9 )
inactive disease status
Timeframe: Treatment Period 2
3.To evaluate PK of secukinumab and 
confirm the predicted dose Secukinumab serum 
concentrations and derived PK 
parameters
Timeframe: Treatment Period 1
4.To evaluate the safety/tolerability 
and immunogenicity of 
secukinumabAEs, laborator y values, vital 
signs, Anti-Drug Antibodies (ADA) 
Timeframe: Entire study

[COMPANY_001] Confidential Page 22
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304

[COMPANY_001] Confidential Page 23
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
3 Investigational plan
3.1 Stud y design
This is a double -blind, placebo -controlled, event -driven randomized withdrawal study  to 
investigate the efficacy  and safet y of secukinumab treatment in the J IA categories of JPsA and 
ERA. The study  is divided into 3 parts (plus a post-treatment follow -up period) consisting of 
open -label, single -arm active treatment in Treatment Periods 1 and 3 and a randomized, 
double -blind, placebo controlle d, event -driven withdrawal design in Treatment Period 2, as 
described below:
Treatment Period 1: A maximum 8-week screening period is used to assess patient 
eligibility . All eligible patients will enter Treatment Period 1 to receive 12-weeks of open -
label secukinumab at a dose predicted to achieve secukinumab serum levels equivalent to 
adults administered a 150 mg dose regimen (see Section 3.3 for details). Secukinumab will be 
administered subcutaneously  (s.c.) weekl y for the first 4 weeks (Baseline, Weeks 1, 
2, 3, 4) 
and then every  4 weeks thereafter. Clinical response (JIA ACR 30) will be assessed at Week 
12. Responders will advance to Treatment Period [ADDRESS_1134927] exit the trial 
(early termi nation visit and enter into the Post
-treatment follow -up period).
Treatment Period 2: Patients with a clinical response (JIA ACR30) at Week 12 will enter 
double -blind withdrawal Treatment Period 2to be randomized 1:1 to either secukinumab or 
placebo on that visit. Treatment Period 2 is event driven and will 
close when 33 patients 
experience a disease flare as per JIA definition (Appendix 8). If Treatment Period 2 is closed 
when a patient becomes eligible to enter Treatment Period 2, the patient will skip Treatment 
Period 2 and advance directly  to Treatment Period 3. When the 33rdflare is observed, all 
investigators will be informed that Treatment Period 2 is closed and all remaining patients 
will enter Treatment Period 3 at their next scheduled visit. Because Treatment Period 2 is 
event driven, it is possible that a patient remai
ns in Treatment Period 2 for the duration of the 
study  (Week 104) before 33 disease flares are observed.  Such patients will complete the 
study  without having entered Treatment Period 3.
Treatment Period 3:Patients experiencing a disease flare in Treatme nt Period [ADDRESS_1134928]-treatment follow -up: All patients completing the study  (Week 104) or who discontinue 
early will enter the Post-treatment follow -up period lasting [ADDRESS_1134929]-treatment follow -up 
visit.
Due to the event driven design of Treatment Period 2, the lengths ofTreatment Periods 2 and 
3 will be variable and patient- specific. Based on the study  design, a patient may  participate in:

[COMPANY_001] Confidential Page [ADDRESS_1134930] discontinue from the study .
2.Treat ment Periods 1, 2, and 3.
3.Treatment Periods 1 and 2 only if the patient never experiences a disease flare after 
randomization into Treatment Period 2 and reaches a total study  duration of 104 weeks 
before a total 33 flares in Treatment Period 2 are observe d.
4.Treatment Periods 1 and 3 only if 33 flares are observed in Treatment Period 2 prior to 
or at the time the patient reaches Week12 (end of Treatment Period 1) and is eligible to 
enter Treatment Period 2.  I n this situation, the patient will enter Treatme nt Period [ADDRESS_1134931]-treatment follow up period, except for those enterin g 
the extension study .
Enrollment will be staggered such that enrollment will be held in each dose weight group (< 
or ≥50kg) when [ADDRESS_1134932] enrolled.  Patients discontinued before 
Week 12 may be replaced. In order to confirm the predicted pediatric dosing regimen, a 
Pharmacokinetics (PK) interim analysis (IA)will be conducted for each of these [ADDRESS_1134933] been 
observed (Treatment Period 2 is completed). 
Treatment : Secukinumab prefilled syringes (PFS), available as a 150mg/1mL  PFS and as a 
75mg/0.5mL  PFS, and matc hing placebo will be used in the study .
Treatment Period 1 open -label : Secukinumab 75 mg (< 50kg, 0.5 mL  PFS) or 150 mg 
(≥50 kg, 1 mL PFS) s.c will be administered at Baseline, Weeks 1, 2, 3, 4, and 8.  The end 
of Treatment Period 1 visit at Week 12 will d etermine if the patient continues directly into 
Treatment Period 2 at that visit (minimum  JI A ACR30 response) to begin blinded study  
drug administration or is not a responder and must have the earl y termination visit 
performed and enter directly into the Post-treatment follow -up period without any  further 
study  drug administration.  
Treatment Period 2 treatment withdrawal : Patients who are a responder (minimum JIA 
ACR30) at the end of Treatment Period 1 visit at Week 12, will move directly into 
Treatment Period 2 at that same visit to be randomized 1:1 to receive blinded 
secukinumab (75mg for < 50kg [ 0.5 mL PFS] or 150 mg for ≥ 50 kg [ 1mL PFS] or 
matching placebo administered in Treatment Period 2 and then every  four weeks until 
either experiencing a disease flare or completion of Treatment Period 2 (33 disease flares 
observed in the overall study  population).  For patients who are eligible to enter Treatment 
Period 2, but it has closed (because 33 disease flares were observed), they  will skip 
Treatment Period 2 and enter directl y into Treatment Period 3 at that visit to begin open-
label secukinumab administration.

[COMPANY_001] Confidential Page 25
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
Treatment Period 3 open -label : Secukinumab 75 mg (< 50 kg, 0.5 mL PFS) or 150 mg ( ≥ 
50 kg, 1mL PFS) s.c will be administered every  4 weeks until Week 100 included.  
Figure 3-1 Study  design
The time point for entering Treatment Period 3 will be either when the patient experiences a 
disease flare, or on/after the completion of Treat ment Period 2. Consequently , the duration in 
Treatment Period [ADDRESS_1134934]-
treatment follow -up visit .
3.2 Rationale for study  design
Although the cause for arthritis in children and adults is not known, children are expected to 
respond similarly  to adults with similar conditions. Data from multiple secukinumab studies 
evaluating a range of doses (75 mg to 300 mg) are available for two adult spondy loarthritides 
(AS (Ank ylosing Spondy litis) and PsA (Psoriatic Arthritis)) and RA (Rheumatoid Arthritis). 

[COMPANY_001] Confidential Page [ADDRESS_1134935] efficacy  in adults with a spondy loarthropathy  (PsA or AS), the appropriate paediatric 
arthritic population to study  secukinumab treatment is children aged ≥ 2 to < 18 years 
diagnosed with enthesitis -related arthritis or juvenile psoriatic arthritis JIA which are the two 
JIA categories which represent pediatric correlates of the approved adult SpA indications. The 
present stud y is adequately  powered to demonstrate effectiveness of secukinumab treatment in 
a placebo- controlled study  design following EMA (European Medicine Agency ) JIA 
treatment guidelines evaluating a paediatric dose regimen equivalent to the 150 mg adult AS 
and PsA dose regimen. No additional safet y risks or vulnerabilities are expected from 
exposure to secukinumab at this dose in the proposed paediatric population. 
The patient population will be described in more detail in the Section 4 below.
3.3 Rationale for dose/regimen, route of administration and duration 
of treatment
The dose selection for secukinumab in pediatric JPsA and ERA is based on the expectation 
that children will respond similarly  to adults with similar conditions.  In the pi[INVESTIGATOR_819418] -controlled studies, 
secukinumab [ADDRESS_1134936] 4 weeks and monthly  thereafter 
demonstrated significant efficacy  and a favorable safet y profile. In both adult AS and PsA, 
secukinumab treatment led to significant improvement in patient’s clinical signs and 
symptoms as well as improved qualit y of life. Based on this data, secukinumab has received 
approval in multiple countries, including the European Union and the US, for these 
indications at this dose.  For adults with PsA, a 300mg dose regimen was a more effective 
dose in treating the psoriasis of patients with moderate to severe skin involvement and in 
treating the arthritic component in patients who did not respond adequately to a TNF inhibitor. 
For both indicati ons, the recommended dose in TNF -α naïve patients is 150 mg by 
[CONTACT_819430] 0, 1, 2 and 3, followed by  [CONTACT_819431] 4 
(Cosenty x®(Secukinumab) label 2016 ) 

[COMPANY_001] Confidential Page 27
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304

[COMPANY_001] Confidential Page 28
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
3.4 Rationale for choice of comparator
A placebo group is included in t his study  at Week 12. Due to the nature of the disease and the 
primary  outcome measure used (JI A ACR30 response), a placebo group is necessary  to obtain 
reliable efficacy  measurements for comparison between the active treatment and placebo 
groups in a controlled fashion. This is in accordance with health authority  guidelines, 
including (EMA 2015) .Placebo exposure is kept to a minimum by  [CONTACT_819432] a disease flare in Treatment Period 2 toTreatment Period 3 where they receive 

[COMPANY_001] Confidential Page 29
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
open -label secukinumab and by [CONTACT_13635][INVESTIGATOR_819419] 2 when 33 flares occur and 
advance all remaining patients to Treatment Period 3 to receive open -label secukinumab.  
3.5 Purpose and timing of interim analy ses/desig n adaptations
A PK interim analy sis will be conducted for the first 10 patients enrolled in each weight dose 
group (< or ≥50kg) after completion of the Week 12 visit in order to confirm the predicted 
pediatric dosing regimen.
Enrollment will be held in each dose weight group (< or ≥ 50kg) when [ADDRESS_1134937] entered Treatment Period 1. Patients discontinued before Week 12 may be 
replaced. Separate PK IAs may be performed depending on enrollment rate in each weight 
dose group. When the adequa cy of the predicted exposure is confirmed, recruitment for that 
weight group will reopen until the planned study  population is fully  enrolled. The interim 
analysis for one or both dose weight groups may not be necessary  if the secukinumab dose is 
confirmed by [CONTACT_819433]. Any change in the 
dose regimen to be implemented based on the PK IA results or available data from the 
ongoing pediatric psoriasis study  will be communicated in written format from [COMPANY_001]. 
3.6 Risks and benefits 
Secukinumab has shown efficacy  in several inflammatory  diseases, including PsA, AS, and 
psoriasis. The large safety  dataset of secukinumab cross -indication did not show unexpected 
safet y issues relative to the known mode of action. In general, secukinumab is safe and well-
tolerated and has demonstrated a similar safet y profile to other mAbs (including etanercept 
and ustekinumab). The most frequently  reported AEs are non-serious infections, especiall y 
upper respi[INVESTIGATOR_36115]. I
n addition, there is an increase in mucosal or cutaneous 
candidiasis with secukinumab compared with placebo, but the cases were generall y mild or 
moderate in severity , non-serious, and responsive to standard treatment. There is also a small 
increase in neutropenia cases with secukinumab compared with placebo. Common 
Terminology  Criteria for adverse event (CTCAE) grade 3 neutropenia (<1.0 -0.5 x 109/L) was 
uncommonly  observed with secukinumab, most were mild to moderate, transient and 
reversible, and without a temporal relationship to serious infections. Hypersensitivity 
reactions include urticaria. Rare events of anaphy lactic reaction to secukinumab have also 
been observed in clinical studies. 
The immunogenicit y potential, e.g. eliciting the production of anti-drug antibodies (ADA) is 
low. In psoriasis, psoriatic arthritis and anky losing spondy litis clinical studies, less than 1% of 
patients treated with secukinumab (n>9600) developed antibodies over up to 52 weeks of 
treatment. 
Taking into account the indiv idual risks as outlined above, the expected risk profile of 
secukinumab from its mechanism of action is anticipated to be similar or improved compared 
to the other approved inflammatory  cytokine -targeting therapi[INVESTIGATOR_014]. The risk to subjects in this 
trial will be minimized by [CONTACT_144941], close clinical monitoring, 
and extensive guidance to the investigators provided by [CONTACT_819434] (IB) for Secukinumab. Based on overall risk -benefit assessment, the 
current trial with secukinumab is justified.

[COMPANY_001] Confidential Page [ADDRESS_1134938] of male and female patients aged from ≥2 years to <18 y ears 
at screening  who are diagnosed with either enthesitis -related arthritis (ERA) based on 
fulfilling the ILAR JI A classification criteria or JPsA based on fulfilling a modified ILAR JIA 
classification criteria. Every  effort will be made in order to randomize at least 20 patients 
from each JIA category  to Treatment Period 2. A 1:[ADDRESS_1134939] ensuring an equal number of patients from each JIA category 
(JPsA and ERA) will receive either secukinumab or placebo treatment . Patients included must 
be biologic treatment naïve and have active disease despi[INVESTIGATOR_819420] D and 
DMARD therap y. 
All non -biologic DMARDs except MTX (or sulfasalazine [SSZ] for ERA patients only ) are to 
be withdrawn with adequate washout before Baseline (see Table 5-1). 
Concomitant therapy  with MTX, (or SSZ for ERA patients only ) and oral corticosteroids (CS) 
will be acceptable at stipulated maximum doses, but the dose and route of administration must 
have been stable for at least four weeks prior to Baseline for the DMARD and 7 days for the 
CS and remain at that dose during the study  Treatment Period 1, while dose adjustments will 
be permitted according to investigator’s judgement in Treatment Period 2 only after 3 
consecutive months of minimum ACR50 response or at an y time in Treatment Period 3. 
A total of approximately 80 patients to Treatment Period 1 in approximately  40 –
50 centers 
worldwide is anticipated to enroll in order to reach the minimum required sample size of 60 
patients in Treatment Period 2 (see also section 9.6). Depending on the responder rate in 
Treatment Period 1 and the dropout rate in Treatment Period
s 1 and 2, more patients may 
need to be enrolled in Treatment Period 1 to reach the 33 flares in Treatment Period 2 . A 20% 
screen failure rate is anticipated which will then require approximate [ADDRESS_1134940] fulfill all of the following criteria:
1.Parent’s or legal guardian’s written informed consent and child’s assent, if appropriate, 
must be obtained before any study related activity or assessment is performed. Of note, if 
the subject reaches age of consent (age as per local law) during the study , they will also 
need to sign the corresponding st
udy I CF (Informed Consent Form).
2.Males and females ≥2 y ears old and <18 years old at the time of screening.
3.Confirmed diagnosis of ERA according to the ILAR classification criteria or JPsA 
according to the modified ILAR classification criteria (See Appendix 7 ) that must have 
occurred at least 6 months prior to Screening.  
4. Active disease (ERA or JPsA) defined as having both: 
≥ 3 active joints (swollen or if not swollen must be both tender and limite d range of 
motion) at Baseline
≥1 site of active enthesitis at Baseline or documented by  [CONTACT_969]  
5.Inadequate response ( ≥1 month) or intolerance to ≥1 NSAI D. 
6.Inadequate response ( ≥2 months) or intolerance to ≥ [ADDRESS_1134941]. 

[COMPANY_001] Confidential Page 31
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
7. No concomitant use of second line agents such as disease- modify ing and/or 
immunosuppressive drugs will be allowed with the exception of the following agents 
which must remain at stable dose during trial Treatment Periods 1 and 2 (See Section 
5.5.7 for additional details and for required wash
-out period):
Stable dose of methotrexate (maximum of 20 mg/ m2BSA/ week) for at least 4 weeks 
prior to the Baseline visit, and folic/folinic acid supplementation (according to 
standard medical practice of the center)
Stable dose of SSZ (ERA patients only ) <50 mg/kg/day  with max of 3000 mg/day  for 
at least 4 weeks prior to the Baseline visit
Stable dose of an oral corticosteroid (CS) at a prednisone equivalent dose of <0.2 
mg/kg/day  or up to  10 mg/day ma ximum, whichever is less, for at least 7 day s prior 
to Baseline
Stable dose of no more than one NSAID for at least 1 week prior to Baseline
8.Negative QuantiFERON (QF) test. Negative Purified Protein Derivative [[COMPANY_003]] test is also 
acceptable if either require d by [CONTACT_819435] <5 years of age. A 
positive [COMPANY_003] is defined as >15mm induration for children > 4 years and >10mm for 
children <4 years.
Subjects with a positive test may  participate in the study  if further work up (according 
to local practice/guidelines) establishes conclusively that the subject has no evidence 
of active tuberculosis. If presence of latent tuberculosis is established then treatment 
according to local country  guidelines must have been initiated and for a minimum o f 
4 weeks before Baseline.
In the absence of local guidelines the US CDC (Centers for Disease Control and 
Prevention) guidelines for treatment of latent TB must be followed i.e. INH 
(isonicotiny lhydrazide ) treatment for [ADDRESS_1134942] ever received biologic immunomodulating agents , including but not 
limited to TNFα inhibitors, T- cell costimulatory , Anti -IL6, Anti -IL1, cell-depleting 
therapi[INVESTIGATOR_90156]- CD20 (e.g., alemtuzumab, anti- CD4, anti -CD5, 
anti-CD3, and anti -CD19), secukinumab or other biologic drugs directly  targeting IL -[ADDRESS_1134943] except for MTX (or sulfasalazine [SSZ] for 
ERA patients only ) (see Section 5.5.7 and Table 5 -1for additional details) .
6.Patients fulfilling an y ILAR diagnostic J IAcategory  other than ERA or JPsA.
7.Patients taking medications prohibited by  [CONTACT_760] (see Section 5.5.8 , 
Table 5-1
)(e.g., topi[INVESTIGATOR_819421] (UV) therapy  at screening). The 
washout periods to be observed before Baseline are given in Table 5-
1.
8.Patients taking high potency  opi[INVESTIGATOR_2467] (morphi ne equianalgesic or higher) 
including but not limited to methadone, hy dromorphone and morphine.
9.Any intramuscular/intravenous/intra -articular corticosteroid treatment within 4 weeks 
before Baseline.
10.Active or recurrent bacterial, fungal or viral infection including known infection with 
Human Immunodeficiency  Virus (HIV), Hepatitis B, and Hepatitis C at Baseline.
11.History  or evidence of active tuberculosis (TB) or evidence of Latent TB (positive 
QuantiFERON or [COMPANY_003] at screening) but unwilling or unable to comp lete a minimum of 4 
weeks of latent TB treatment before initiating treatment with secukinumab. 
12.History  or current diagnosis of Electrocardiogram (ECG) abnormalities indicating 
significant risk of safet y for patients participating in the study  such as:
Concomitant clinically  significant cardiac arrhy thmias, e.g., sustained ventricular 
tachycardia, and clinically  significant second or third degree AV block without a 
pacemaker
History  of familial long QT sy ndrome or known family  history  of Torsades de Pointe s
13.Pregnant or nursing (lactating) females, where pregnancy  is defined as the state of a 
female after conception and until the termination of gestation, confirmed b y a positive
hCG laboratory  test.
14.Female patients (< 18 years of age) of childbearing potenti al (menarchal or becoming 
menarchal during the study ) who do not agree to abstinence or, if sexually  active, do not
agree to the use of contraception as defined in Section 6.5.7 .
15.Active ongoing inflammat ory diseases other than JPsA / ERA that might confound the 
evaluation of the benefit of secukinumab therap y.
16.Underl ying metabolic, hematologic, renal, hepatic, pulmonary , neurologic, endocrine, 
cardiac, infectious or gastrointestinal conditions which in th e opi[INVESTIGATOR_2511] I nvestigator 
immunocompromises the subject and/or places the subject at unacceptable risk for 
participation in a study  with an immunomodulatory  treatment.
17. Significant medical problems or diseases, including but not limited to the following : 
uncontrolled hy pertension and uncontrolled diabetes (can be discussed on a case -by-case 
basis with [COMPANY_001]).
18.History  of clinically  significant liver disease or liver injury  as indicated b y abnormal liver 
function tests (LFT) such as aspartate aminotrans ferase/serum glutamic oxaloacetic 
transaminase (AST/SGOT), alanine aminotransferase/ serum glutamic p yruvic 
transaminase (ALT/SGPT), alkaline phosphatase, or serum bilirubin. The Investigator 
should be guided b y the following criteria:

[COMPANY_001] Confidential Page 33
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
a.Any single parameter may not exceed 2 x upper limit of normal (ULN). A single 
parameter elevated up to and including [ADDRESS_1134944] prior to baseline, to rule out lab error.
b.If the total bilirubin (TBL) concentration is increased above [ADDRESS_1134945] reacting bilirubin. In any  case, 
serum bilirubin should not exceed the value of 1.6 mg/dL (27 µmol/L ).
19.Screening total white blood cell (WBC) co unt < 3 000/µL , or platelets < 100 000/µL  or 
neutrophils < 1 500/µL  or hemoglobin < 8.5 g/dL (85 g/L).
20.History  of lymphoproliferative disease or an y known malignancy  or history  of malignancy  
of an y organ s ystem within the past 5 y ears (except for basal cel l carcinoma or actinic 
keratoses that have been treated with no evidence of recurrence in the past [ADDRESS_1134946] been 
removed).
21.Current severe progressive or uncontrolled disease which in the judgment of the clinical 
Investigator renders the subject unsuitable for the trial.
22.Inability  or unwillingness to undergo repeated venipuncture (e.g., because of poor 
tolerability  or lack of access to veins).
23.Any medical or ps ychiatric conditi on which, in the investigator’s opi[INVESTIGATOR_1649], would preclude 
the participant from adhering to the protocol or completing the study  per protocol (can be 
discussed on a case -by-case basis with [COMPANY_001]).
24.History  or evidence of ongoing alcohol or drug abuse, within the last six months before 
Baseline.
25.Plans for administration of live vaccines during the study  period or within 6 weeks 
preceding Baseline.
5 Treatment
5.1 Stud y treatment
5.1.1 Investigational and control drugs
[COMPANY_001] will supply  the following study  drugs:
Investigational treatment
Secukinumab 150 mg/1 mL , liquid formulation provided in 1 mL PFS 
Secukinumab 75 mg/0.5 mL , liquid formulation provided in 0.5 mL PFS 
Reference treatment
Placebo, liquid formulation in a 1 mL  and 0.5 mL PFS
Secukinumab 75 mg/0.5 mL and 150 mg/[ADDRESS_1134947] identical appearance 
All study  drugs will be labeled accordingl y:
For the open- label parts (Treatment Periods 1 and 3):

[COMPANY_001] Confidential Page 34
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
AIN457 150 mg/1 mL
AIN457 75 mg/0. 5mL
For the double -blind part (Treatment Period 2):
AIN457 150 mg/1 mL /Placebo
AIN457 75 mg/0.5 mL /Placebo
For detailed instructions on storage of the stud y drugs, please refer to Section 5.5.3
5.1.2 Additional treatment
No additional treatment bey ond investigational drug and control drug are included in this trial.
5.2 Treatment arms
Patients will enter Treatment Period 1 to receive 12-weeks open label active treatment of 
either s.c. sec ukinumab 75 or 150 mg, based on their body  weight (< 50 kg or ≥ 50 kg) at each 
dosing visit starting at Baseline. They  will receive further doses at Weeks 1, 2, 3, 4, and 8. 
At the End of Treatment Part [ADDRESS_1134948] be per formed and 
ACR response criteria 
evaluated to determine future patient disposition in the study .  Patients 
who are assessed as a responder (minimum JI A ACR30 response) will enter Treatment Period 
2 at that same visit to be randomized to either continue their active treatment or matching 
placebo every  4  w eeks, in a blinded manner, in a 1:[ADDRESS_1134949]-
treatment follow -up p eriod at that visit without receiving any further study  drug 
administration. 
Patients will enter Treatment Period 3 from Treatment Period 2 because of either experiencing 
a flare or when 33 flares in Treatment Period 2 are overall observed and Treatment P eriod 2 is 
closed. Patients in Treatment Period 1 when Treatment Period 2 closes will skip Treatment 
Period 2 and advance directl y into Treatment Period 3 after successfully  completing 
Treatment Period 1. During Treatment Period 3, patients will receive op en-label secukinumab 
(either 75 or 150 mg, based on body  weight) every 4 weeks until study  Week 100 is reached. 
5.3 Treatment assignment and randomization 
All patients fulfilling all entry  criteria will be assigned to AIN457/secukinumab 75 or 150 mg, 
based on body  weight (< 50 kg or ≥ 50 kg) and continue to receive an appropriate 
secukinumab dose at each visit based on their weight at that visit. At the Week 12 visit, all 
responders will be eligible to enter Treatment Period 2 where they will be randomized vi a 
Interactive Response Technology  (IRT) to one of the two treatment arms, active as 
secukinumab 75 or 150 mg, or matching placebo based on their weight at that visit. 
In Treatment Period 2, patients will be randomized by [CONTACT_819436]  (strata: JPsA and 
ERA) in a 1:[ADDRESS_1134950] bli nded dose based on their weight at that visit.
The Investigator or his/her delegate will contact [CONTACT_819437]. The IRT will assign a randomization number to the patient, 
which will be used to linkthe patient to a treatment arm and will specify  a unique medication 
number for the first package of study  drug to be dispensed to the patient. The randomization 
number will not be communicated to the caller.
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from patients/parents and Investigator staff. 
A patient randomization list will be produced by [CONTACT_6609] a validated system 
that automates the random assignment of patient numbers to randomization numbers. These 
randomization numbers are linked to the different treatment arms and to study  strata, which in 
turn are linked to medication numbers. A separate medication list will be produced by [CONTACT_819438] y Management using a validated system that 
automates the random assignment of medication numbers to packs containing the 
investigational drug(s). 
The randomization scheme for patients/subjects will be reviewed and approved by a member 
of the Randomization Group.
5.4 Treatment blinding 
Patients/parents, Investigator staff, persons performing the assessments, and data analy sts will 
remain blinded to the identity  of the treatment (Treatment Period 2) from the time of 
randomizati on until database lock, using the following methods:
(1) Randomization data are kept strictly  confidential until the time of unblinding, and will not 
be accessible by [CONTACT_819439], 
independent stati stician, programmer and DMC (Data Monitoring Committee) members.
(2) The identity  of the treatments will be concealed by [CONTACT_819440], labeling, schedule of administration, administration route and 
appearance.
Unblinding will only  occur in the case of patient emergencies (see Section 5.5.9) and after the 
primary  efficacy  anal ysis. 
5.[ADDRESS_1134951] Number will not be reused. 

[COMPANY_001] Confidential Page 36
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
Upon signing the informed consent form, the patient is assigned the next sequential number 
by [CONTACT_093]. The Investigator or his/her staff will contact [CONTACT_105244]. The site must 
select the CRF book with a matching Subject Number from the Electronic Data Capture ( EDC )
system to enter data. 
If the patient fails to be treated for any reason, the IRT must be notified within [ADDRESS_1134952] 
number. For all subjects, the investigato r/qualified site staff will record if the subject was 
rescreened on the rescreening CRF page and any applicable screening numbers the subject 
was issued prior to the current screening number.
5.5.2 Dispensing the study drug 
Each stud y site will be supplied with study  drug in packaging of identical appearance.
The study drug packaging has a 2-part label. A unique medication number is printed on each 
part of this label which corresponds to placebo or active treatment. Investigator staff will 
identify  the study  drug package(s) to dispense to the patient by [CONTACT_18608](s). Immediatel y before dispensing the package to the patient, 
Investigator staff will detach the tear-off part of the label from the packaging and affix it to 
the source document (Drug Label Form) for that patient’s unique subject number. For deliver y 
of IMP to a participant's 
home, the pharmacist/qualified site personnel will dispense, via IRT, 
the investigational treatment package and detach outer part of the label from the packagin g 
and affix it to the source document for that patient’s unique subject number.
During a major health care disruption (e.g., COVID 19 pandemic/epi[INVESTIGATOR_901]) that limits or 
prevents on-site study  visits, delivery  of IMP directly  to a participant’s home would be 
permitted in the event the Investigator has decided that an on -site visit by  [CONTACT_819441], and that it is in the interest of the participant’s health to 
administer the study  treatment even without performing an on-site visit.  Delivery  of IMP 
directly  to a participant’s home would be permitted only  during the duration of the health care 
disruption and for patients 
whom the Investigator deems that delay ing/skippi[INVESTIGATOR_007] a dose is not 
an option. The shipment/provisioning will be for a maximum quantity  covering a 1-month 
supply .
In this case, regular phone calls or virtual contacts (every  4
 weeks or more frequentl y if 
needed; prior to drug shipment and just before dosing) will occur between the site and the 
participant for instructional purposes, safet y monitoring, and discussion of the participant´s 
health status until the participant can again visit the site. Where home dosing is performed, 
patient’s body  weight will be collected and transmitted to the site prior to shipment. 
Appropriate safet y assessments (e.g., evaluation of AEs and SAEs) should be conducted after 

[COMPANY_001] Confidential Page 37
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
the dose is administered. Scheduled efficacy assessments are not required for home 
administration. 
The dispatch of IMP from the site to the participant’s home remains under the accountabilit y 
of the Investigator. Home administration can be performed by [CONTACT_65956]/guardian/caregiver, provided they are familiar or have been trained on how to inject 
with the PFS as per investigator s judgment. The patient/parent/guardian/caregiver should be 
provided with the PFS Instructions For Use.
It must be noted that subjects 12-<[ADDRESS_1134953] only under 
Parent/Guar dian/Caregivers or health care professional supervision. Subjec ts < 12 years of 
age should not self 
–inject.
5.5.3 Handling of study  and additional treatment 
[IP_ADDRESS] Handling of study  treatment
Study  treatment must be received by a designated person at the study  site, handled and stored 
safel y and properl y, and kept in a secured location to which only the Investigator and 
designees have access. Upon receipt, all study  treatment must be stored according to the 
instructions specified on the labels. Clinical supplies are to be dispensed only in accordance 
with the protocol. Technical complaints are to be reported to the respective [COMPANY_001] Country 
Pharma Organization (CPO) Quality  Assurance.
Medication labels will be in the local language and comply  with the legal requirements of 
each country . They  will include storage conditions for the study  treatment but no information 
about the patient except for the medication number .
The Investigator must maintain an accurate record of the shipment and dispensing of study 
treatment in a drug accountability  log. Monitoring of drug accountability  will be performed by 
[CONTACT_18609]. Patients/subjects will 
be asked to return all unused study  treatment and packaging at the end of the study  or at the 
time of discontinuation of study  treatment.
At the conclusion of the study , and as appropriate during the course of the study , the 
Investigator will return all unused study  treatment, packaging, drug labels, and a copy  of the 
completed drug accountability  log to the [COMPANY_001] monitor or to the Novar tis address provided 
in the I nvestigator folder at each site.
[IP_ADDRESS] Handling of additional treatment  
Not applicable.
5.5.4 Instructions for prescribing and taking study treatment
Study  treatment (secukinumab 75 mg, 150 mg or placebo) will be administered by s.c. PFS
throughout the study . Administration of study  treatment will occur at the study  site for the 
whole study  duration (104 weeks ), except in cases of a major healthcare disruption that 
impedes on-site drug administration. Apart for the exceptional circumstances created by [CONTACT_819442], administration of study  treatment must occur 

[COMPANY_001] Confidential Page [ADDRESS_1134954] been completed, and with the timing 
indicated in Table 6-1 (Assessment Schedule).
The first study  treatment administration will occur at the Baseline visit only after eligibility 
criteria have been confirmed, all study  baseline assessments have been performed, and the 
scheduled blood samples have been drawn. At each subsequent visit, all study  assessments (as 
applicable per Table 6-1) should be completed prior to the injection of study  treatment. 
Administration of study  treatment should occur after sample collection for PK assessments (at 
visits specified in Table 6 - 1).
All invest igational treatment kits assigned by [CONTACT_669453]. The 
Investigator must promote compliance by [CONTACT_710495]/guardian to attend 
the study  
visits as scheduled and by [CONTACT_131557]’s safety and the 
validity  of the study . The subject/guardian should be instructed to contact [CONTACT_188636]/she is unable for an y reason to attend a stud y visit as scheduled. 
During a major health care disruption (e.g., COVID 19 pandemic / epi[INVESTIGATOR_901]) that limits or 
prevents on-site study  visits, delivery  of IMP directly  to a participant’s home would be 
permitted in the event the Investigator has decided that an on -site visit by  [CONTACT_819441], and that it is in the interest of the participant’s health to 
administer the study  treatment even without performing an on-site visit.  Delivery  of IMP 
directly  to a participant’s home would be permitted only  during the duration of the health care 
disruption and for patients whom the Investigator deems that delay ing/skippi[INVESTIGATOR_007] a dose is not 
an option. The shipment/provisioning will be for a maximum quantity  covering a 1-month 
supply .
In this case, regular phone calls or virtual contacts (every  4
 weeks or more frequentl y if 
needed; prior to drug shipment and just before dosing) will occur between the site and the 
participant for instructional purposes, safet y monitoring, and discussion of the participant´s 
health status until the participant can again visit the site. Where home dosing is performed, 
patient’s body  weight will be collect ed and transmitted to the site prior to shipment. 
Appropriate safet y assessments (e.g., evaluation of AEs and SAEs) should be conducted after 
the dose is administered. Scheduled efficacy assessments are not required for home 
administration. 
The dispatch of IMP from the site to the participant’s home remains under the accountabilit y 
of the Investigator. Home administration can be performed by [CONTACT_65956]/guardian/caregiver, provided they have been trained on how to inject with the PFS as 
per investigators judgment. The patient/parent/guardian/caregiver should be provided with the 
PFS I nstructions For Use.
It must be noted that subjects 12-<[ADDRESS_1134955] only under 
Parent/Guardia n/Caregivers or health care professional supervision. Subjects < 12 years of 
age should not self 
–inject.
For the visits where a urine pregnancy  test is required or deemed necessary , if the patient 
cannot visit the site to have urine pregnancy  test done, the urine pregnancy test kit can be 
provided to the patient/parent/guardian/caregiver or shipped directl y to the their home (e.g., 
together with the study  drug). After appropriate instruction, patient/parent/guardian/caregiver 

[COMPANY_001] Confidential Page [ADDRESS_1134956] is confirmed prior to the administration of the study  drug. 
The patient/parent/guardian/caregiver will record the date of administration and will return the 
packaging at their next visit to the site. Used syringes should be disposed immediately  after 
use in a sharps container OR according to the regulatory  requirements in the respective 
country .
Site staff are to transcribe this information into the appropriate Dosage Administration Record 
eCRF. The investigator must maintain an accurate record of the shipment and dispensing of 
study  treatment in a drug accountabilit y log.
In case a flare is suspected between two scheduled visits in Treatment Period 2, the patient 
can be evaluated at that time by [CONTACT_819443].  If a flare is 
confirmed at that visit, he/she will advance to Treatment Period 3and receive open -label 
secukinumab at a dose according to their body  weight. Subs equent visits will be carried out as 
scheduled.
Should a visit be delay ed, every  attempt should be made to bring the patient back on schedule 
for the next visit (referring to Baseline visit).
5.5.5 Permitted dose adjustments and interruptions of study  treatment
Study  treatment dose adjustments are not permitted. For subjects who are unable to tolerate 
the protocol -
specified dosing scheme (including subjects who in the opi[INVESTIGATOR_819422] y interr upted), study 
treatment interruption is permitted in order to keep the subject on study  drug. In such cases, 
study  treatment should be interrupted only during the time that a risk is present and ongoing. 
Study  treatment can be restarted at the next schedul ed visit after resolution of the safet y risk.
The effect of secukinumab on live vaccines is unknown; therefore live vaccines should not be 
administered during participation in the study . In case a live vaccine has been administered 
due to a medical urgency , study  treatment should be interrupted for [ADDRESS_1134957] will be restricted from receiving necessary 
rescue medications for lack of benefit or worsening of disease, subjects will be discontinued 
from the study  if treated with prohibited medications (as described in Section 5.5.8) and 
should complete an Early  termination visit at the earliest 
possible time-point and enter the 
Post-treatment follow -up period. Efficacy  and safety  will be assessed in detail at every  study 
visit and, subjects who are deemed by [CONTACT_819444], or for any reason on the subject’s own accord, will be free to discontinue study 
participation at an y time.

[COMPANY_001] Confidential Page [ADDRESS_1134958] the patient/guardian to notify  the study  site about any new 
medicat ions the patient takes after he/she was enrolled into the study . All medications, 
procedures and significant non-drug therapi[INVESTIGATOR_014] (including physical therap y and blood 
transfusions) administered after the patient was enrolled into the study  must be recorded in the 
concomitant medications/significant non-drug therapi[INVESTIGATOR_144924]. 
Each concomitant drug must be individually  assessed against all exclusi on 
criteria/prohibited 
medication. If in doubt the Investigator should contact [CONTACT_188629] a patient or allowing a new medication to be started. Medications /treatments not 
explicitly  mentioned in the protocol can be evalu ated by  [CONTACT_819445] a case -by-case basis.
Guidelines for the use of specific medications are provided below.
Leflunomide wash -out w ith cholesty ramine
In case of leflunomide treatment before study  Baseline , a drug wash -out of [ADDRESS_1134959] be 
performed. However, another wash -out procedure can be considered. Cholesty ramine may be 
given orally at a dose of 8 g three times daily (t.i.d) to wash -out leflunomide. Cholesty ramine 
reduced plasma levels of the active leflunomide metaboli te by  [CONTACT_3450]  40% in 24 hours 
and by 49% to 65% in [ADDRESS_1134960] can be safel y enrolled 4 weeks after the 
beginning of the 11 -day treatment period.
Non- biologic DMA RDs (limited to MTX or SSZ) 
All non -biologic DMARDs, with the exception of stable dose of SSZ (for ERA patients only ), 
or MTX are prohibited as concomita nt medications and must undergo a washout period before 
Baseline administration, as indicated in Table 5 -1.
Concomitant MTX (maximum of 20 mg/ m2/ BSA week) and folic/folinic acid 
supplementation (accordi ng to standard medical practice of the center), or SSZ 
(only for ERA 
patients, stable dose of < 50 mg/kg/day  and up to max 3000 mg/day ) treatment may  be used if 
the dose and route of administration are stable for at least 4 weeks before the Baseline visit 
and remain stable for the duration of the study . Dose reductions are permitted only in case of 
adverse events.  
Systemic corticosteroids
Treatment with oral corticosteroids ≤ 0.2 mg/kg/day (or maximum 10 mg/da y whichever is 
lower) of oral prednisone (or equivalent) is permitted if the dose was stable at least [ADDRESS_1134961] 3 consecutive months of minimum 

[COMPANY_001] Confidential Page 41
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
ACR50 response and at any time in Treatment Period 3based on investigator clinical 
judgment. No corticosteroid dose tapering will be allowed in Treatment Period 1 . 
Any change in the dose of oral corticosteroids during the trial should be recorded on the 
corresponding eCRF page.
Intra -articular corticosteroid injections are not permitted within 4 weeks prior to Baseline or at 
any time in Treatment Period 1 or 2.  Intra-articular corticosteroid injections will be permitted 
in Treatment Period 3.  No more than 4 joints per 24-week period may be injected and no 
single injection should exceed 40 mg of triamcinolon e (or equivalent) during any 52-week 
period.
Non
-steroidal anti -inflammatory  drugs (NSA IDs) (including selective COX -2 
inhibitors), low strength opi[INVESTIGATOR_250314]/paracetamol
Subjects are permitted to enter the trial using regular dose of a single NSAID for their arthritis.   
The dose must be stable for at least 1 week before the baseline visit and remain atthis dose 
during the trial.  Other NSAIDs, low strength opi[INVESTIGATOR_2438], and paracetamol/acetaminophen are 
permitted during the trial only if used on an as required (PRN) basis for non-arthritis 
treatment.  In such cases, the subject must refrain from intake of the PRN medication durin g 
at least [ADDRESS_1134962] and/or safet y interactions. 
Note: Live vaccination is NOT allowed within [ADDRESS_1134963] study  dose. Killed or inactivated vaccines may be permitted 
according to the investigator’s discretion.
It is recommended not to initiate biologic treatment until [ADDRESS_1134964] dose of study 
drug. Therefore, biologic treatment s hould not be used any  time during study  participation.
Table 5-1 Prohibited medication
Medication Prohibition period / washout 
before baselineAction taken
Any biologic drugs, including but 
not limited to TNFα inhibitors, 
secukinumab, or other biologic 
drug directly targeting IL -[ADDRESS_1134965] (bDMARDs)Previous exposure at any time: 
exclusion criterion Discontinue investigational 
treatment
Any cell -depleting therapi[INVESTIGATOR_750612] -
CD20 or investigational agents 
[e.g., alemtuzumab (Campath), 
anti-CD4, anti -CD5, anti -CD3, 
and anti -CD19].Previous exposure at any time: 
exclusion criterionDiscontinue investigational 
treatme nt
Conventional DMARDs (except 
SSZ (for ERA only) or MTX) 4 weeks Discontinue investigational 
treatment

[COMPANY_001] Confidential Page 42
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
Medication Prohibition period / washout 
before baselineAction taken
including apremilast 
Leflunomide [ADDRESS_1134966] has 
returned to baseline or 5 half -lives 
(whichever is longer)Discontinue investigational 
treatment
Analgesics other than NSAIDs, 
paracetamol/acetaminophen, 
and low strength opi[INVESTIGATOR_232097] 2 weeks
Systemic corticosteroids at a 
prednisone equivalent dose of 
≤0.2 mg/kg/day or up to 10 
mg/day maximum, whichever is 
less, is permitted if the dose is 
stable at least 7 days before 
baseline. 
*Corticosteroid dose can be 
tapered down to discontinuation 
in Treatment Period 2 for 
patients with 3 consecutive 
months of minimum ACR50 
response or at any time in 
Treatment Period 3 based on 
investigator judgment. No 
chang es in corticosteroid dose 
will be allowed in Treatment 
Period 1.1 week If administered due to a 
medical urgenc y unrelated 
to the patient’s arthritis, 
study treatment should be  
interrupted until the steroid 
is discontinued –if not 
medical urgenc y or if 
related to the patient’s 
arthritis, then discontinue 
from the study may be 
required on a case by [CONTACT_17878]. 
Intra-articular corticosteroids are 
not permitted within 4 weeks 
prior to baseline or at any time 
in Treatment Period 1 or 2.  
Intra-articular co rticosteroid 
injections will be permitted in 
Treatment Period 3 but no more 
than 4 joints per 24 -week period 
may be injected and no single 
injection should exceed 40 mg 
of triamcinolone (or equivalent) 
during any 52 -week period. The 
joints injected with intra -articular 
corticosteroids will be assessed 
as both swollen and tender in 
the SJC and TJC, from injection 
time onwards.4 weeks Discontinue investigational 
treatment, (see Section 
5.5.7 )
Intramuscular or intravenous 
corticosteroid treatment are not 
permitted4 weeks Discontinue investigational 
treatment or from study 
may be required on a case 

[COMPANY_001] Confidential Page 43
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
Medication Prohibition period / washout 
before baselineAction taken
by [CONTACT_413].
Live vaccinations 6 weeks Discontinue investigational 
treatment for 12 weeks and 
patient should remain in 
the study and follow visit 
schedule.
Oral or topi[INVESTIGATOR_22775] 4 weeks Discontinue investigational 
treatment
Photochemotherapy (e.g. 
PUVA)4 weeks Discontinue investigational 
treatment
Phototherapy (UVA or UVB) 2 weeks Discontinue investigational 
treatment
Topi[INVESTIGATOR_19623] (except 
in face, eyes, scalp and genital 
area during screening period 
only, and if topi[INVESTIGATOR_030],  only those with 
mild to m oderate potenc y)[ADDRESS_1134967] often, study  treatment discontinuation and knowledge of the possible 
treatment assignments are sufficient to treat a study  patient who presents with an emergency 
condition. Emergency  treatment code breaks are performed 
using the IRT. When the 
Investigator contacts the system to break a treatment code for a patient, he/she must provide 
the requested patient identify ing information and confirm the necessity  to break the treatment 
code for the patient. The Investigator will then receive details of the investigational drug 
treatment for the specified patient and a fax or email confirming this information. The system 
will automatically  inform the [COMPANY_001] monitor for the site and the Study Team that the code 
has been broken.
It is the investigator’s responsibility  to 
ensure that there is a dependable procedure in place to 
allow access to the IRT/code break cards at any time in case of emergency . The Investigator 
will provide:
protocol number
study  drug name (if available)
patient number
In addition, oral and written information to the subject/guardian must be provided on how to 
contact [CONTACT_5657]/her backup in cases of emergency , or when he/she is unavailable, to ensure that 
un-blinding can be performed at an y time. 
Study  drug must be discontinued in Treatment Period [ADDRESS_1134968]’s completion or premature discontinuation of the study  and the 
reason for discontinuation of the study  will be recorded on the appropriate eCRFpage.  
Addit ionally , the investigator or site staff must contact [CONTACT_819446]’s study  completion and/or discontinuation.
The Investigator must provide follow -up medical care for all subjects who are prematurel y 
withdrawn from the study, or must refer them for appropriate ongoing care. This care may 
include initiating another treatment outside of the study  as deemed appropriate by [CONTACT_1275]. This treatment may be any non-biologic DMARD. In case of a biologic 
treatment, a waiting period of [ADDRESS_1134969] discontinue study  treatment for a given patient if, on balance, he/she 
believes that continuation would negativel y impact the ris k/benefit of trial participation.
Study  treatment must be discontinued under the following circumstances: 
Patient/Guardian wish  /withdrawal of informed consent
Pregnancy  (see Section 6.5.7 and Section 7.6)
Use of prohibited treatment as per recommendations in Table 5
-1
Any situation in which study  participation might result in a safet y risk to the pa tient
Emergence of the following adverse events: 
Any severe or serious AE that is not compatible with administration of study  
medication, including AEs that require treatment with an unacceptable co -medication
Onset of ly mphoproliferative disease or an y malignancy  except for treated basal cell 
carcinoma, treated actinic keratoses, treated in situ carcinoma of the cervix or non -
invasive malignant colon poly ps which are being or have been removed
Life-threatening infection
Severe h ypersensitivity  reaction o r anaph ylactic reaction
Any laboratory  abnormalities that in the judgment of the Investigator are clinically  
significant and are deemed to place the subject at a safet y risk for continuation in the study  
(A general guidance on clinically  notable laboratory values is provided in Appendix 1 ).
Use of an y biologic immunomodulating agent except secukinumab
Any protocol deviation that results in a significant risk to the subject’s safety .

[COMPANY_001] Confidential Page [ADDRESS_1134970] study  drug administration, for a premature discontinuation visit and 12 weeks after 
“last study drug administration ” for a Post-treatment follow -up visit. Assessments performed 
at these two visits are detailed in the “premature discontinuation visit” and “Post -treatment 
follow -up visit” respectively  in Table 6-
1and should be completed and recorded in the 
appropriate eCRF page. The Investigator must determine the primary  reason for the patient’s 
premature discontinuation of study  and record this information on the Dosage Administration 
eCRF page and also contact [CONTACT_105253]’s discontinuation from study 
treatment. 
If the patient /guardian cannot or is unwilling to attend any visit(s), the site staff should 
maintain regular telephone contact [CONTACT_10970]/guardian , or with a person pre-designated 
by [CONTACT_102] /guardian. This telephone contact [CONTACT_37283] y be done according to the 
study  visit schedule.
If study  drug discontinuation occurs because treatment code has been broken, please refer to 
Section 5.5.9.
5.6.3 Withdrawal of informed consent
Patients in consultation with the guardian or the guardian may voluntarily withdraw patient’s 
consent to participate in the study  for any reasons at any time, without being obliged to give 
any explanation. Withdrawal of consent from the study  is defined as when a patient/guardian:
Does not want to participate in the study  anymore
and
Discontinues all elements outlined in the protocol
and
Does not want an y further visits or assessments
and
Does not want an y further study  related contacts
and
Does not allow anal ysis of already  obtained biologic material 
In this situation, the Investigator must make every  effort (e.g. telephone, e
-mail, letter) to 
determine the primary  reason for the patient/guardian’s decision to withdraw his/her consent 
and record this information. 
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.  All biological 
material that has not been anal yzed at the time of withdrawal must not be used. 
Further attempts to contact [CONTACT_18618] -up.

[COMPANY_001] Confidential Page 46
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the patient’s study  withdrawal should be made as detailed in 
Table 6-1.
5.6.4 Loss to follow -up 
For subjects whose status is unclear because they  fail to appear fo r study  visits without stating 
an intention to discontinue or withdraw, the Investigator should show "due diligence" by 
[CONTACT_762]/guardian, e.g. dates of 
telephone calls, registered letters, etc. A patient cannot be considered as lost to follow -up until 
the time point of his/her scheduled end of study  visit has passed.
5.6.5 Early  study termination by  [CONTACT_819447]. This may  include reas ons 
related to the benefit risk assessment of participating in the study , practical reasons, or for 
regulatory  or medical reasons (including slow enrolment). Should this be necessary , the 
patient must be seen as soon as possible and treated as a premature subject withdrawal (PSW) 
(see Table 6-1). The Investigator may be informed of additional procedures to be followed in 
order to ensure that adequate consideration is given to the protection of the 
patient ’s interests. 
The Investigator will be responsible for informing the Institutional Review Board/Independent 
Ethics Committee (I RBs/IECs) of the earl y termination of the trial.
6 Visit schedule and assessments
Table 6-1lists all of the assessments and indicates with an “x” or an “s” when the visits are 
performed. The “x” indicates data collected on the eCRF page , the “s” indicates data collected 
in the source documents only .
Patients must be seen for all visits on the designated day , or as close to it as possible.
Should a visit be delay ed, every  attempt should be made to bring the patient back on schedule 
for the next visit (referring to Baseline visit). 
For v isits scheduled through Week 4, the stud y treatment should not be administered less 
than 5 days from the previous administration.
For visits scheduled after Week 4, the study treatment should not be administered less than 
[ADDRESS_1134971] study  drug administration, at which time all of the assessments listed for the Week 
104/PSW visit) will be performed and a visit [ADDRESS_1134972] study  drug administration at 
which time all of the assessments listed for the Week 104/Post -Treatment safety  follow up
visit will be performed. At this final visit, all dispensed investigational product should be 
reconciled and the adverse event and concomitant medications reconciled on the eCRF page.
If patients /guardians refuse to return for these assessments or are unable to do so, every effort 
should be made to contact [CONTACT_18622] a knowled geable informant by [CONTACT_819448]. Attempts to contact [CONTACT_102]/guardian should be recorded in the source 

[COMPANY_001] Confidential Page 47
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
documentation. Patients/guardians will be contact[CONTACT_15025] y evaluations during the [ADDRESS_1134973] administration of study  treatment. 
In the event of a major health care disruption (e.g., pandemic, epi[INVESTIGATOR_901]) that limits or 
prevents on-site study  visits, regular phone calls or virtual contacts (every  4 weeks or more 
frequentl y, if needed) will occur until the subject can again visit the site. Events qualify ing for 
being reported in the case report form (e.g., AE, 
procedure) should be entered as appropriate.  
Special effort should be made to collect information related to TD/PSW visits. If it is not 
feasible to conduct the TD or the PSW visit on -site, phone calls should be attempted instead.
Screening will be flexible in duration based on the time required to wash out prior anti-
rheumatic medications and have duration of up to [ADDRESS_1134974] be evaluated for eligibility and allowed sufficient time for potential 
medication washout (see Table 5-1, in addition to all other assessments indicated in Table 6-
1). 
Screening will consist of two 
consecutive visits. During the first screening visit, initial 
assessments will be perfor med as outlined inTable 6-1. At that visit the duration of the 
washout period will be determined. The second screening visit w
ill be performed as follows:
If the washout period is ≤ 4 weeks the investig ator should proceed directl y to Screening 
visit 2 on the same day and complete all assessments within the next 4 weeks prior to 
Baseline.
If the washout period is more than 4 weeks, the patient/guardian will be instructed to 
initiate necessary  washout regimen and return for Screening visit [ADDRESS_1134975] pass from the date of screen failure and the date of 
rescreening, but > [ADDRESS_1134976] be approved by [CONTACT_819449] a case by [CONTACT_413] (see also 
Section 5.5.1).
For rescreened patients, a new ICF has to be obtained. The date of the new informed consent 
signature [CONTACT_819466]. Informed Consent for a rescreened subject must be obtained prior 
to performing an y stud y related assessment or collecting an y data for the Screening Visit.
For rescreening, 
all screening assessments must be performed as per protocol, except for the 
tuberculosis (TB) work up, if applicable, if performed within [ADDRESS_1134977]. 

[COMPANY_001] Confidential Page 48
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
At the discretion of the investigator, laboratory  assessments at Baseline visit need not to be 
performed if screening laboratory  assessments were performed within 7 days from Baseline. 
Urine pregnancy  for appropriate female patients and local CRP assessments should be 
performed at Baseline.
Suggested order of assessments:
Suggested guidelines for conduct of the visit assessments are be low:
Laboratory  sample collection, including local CRP sample 
Parent/Guardian/Subject to complete patient reported outcomes (PRO) at the study  site 
prior to an y other stud y assessments.
Investigator to complete investigator assessments
ACR components sent centrally  for ACR derivation/flare occurrence  -results must 
be reviewed prior to Week 12/Treatment Period 2 administration of study  treatment
Physical exam (at applicable visits)
All remaining stud y visit procedures (e.g. vital signs measurements) must be completed 
prior to study  treatment dosing.
Contact I RT to register the subject visit, as applicable
Administration of study  treatment, as applicable

[COMPANY_001] Confidential Page 49
Amended Protocol Version v02 Clean Protocol No. C AIN457F2304
Table 6-1 Assessment schedule
Screening1Treatment Period 1 Treatment Period 2 / 3 (Primary  Treatment 
Period)
(Note: a patient enters Tx Period 3 in case 
of flare or when Tx Period 2 completes)Unscheduled 
visit Post -
Treatment 
Safety  
follow -up Notes
1 2
Week Up 
to 
-8-4 to 
BLBL 1 2 3 4 8 12/
PSW16 
to 
2024 28 
to 
4852 56 
to     
7276 80 
to 
100104 / 
TD/ 
PSW12 Weeks 
after last  
study  drug 
dosed
Informed consent 
and optional PG 
informed consentX
Inclusion/exclusion 
criteriaX2X2X2
Demography X
JPsA/ ERA date of 
diagnosisX
Cardiovascular 
HistoryX X2X2
Smoking History X X2X2
Relevant Medical 
History / current 
medical conditionsX X2X2
Prior / Concomitant 
Medications and 
non-drug therapi[INVESTIGATOR_21055] X Update as necessary
Surgeries and  non -
drug  proceduresX X Update as necessary
Washout evaluation
instructionS
Physical Examination S S S S S S S S S S S S
Height X X X X X X X
Weight X X X X X X X X X X X X X X X X X X For correct 

[COMPANY_001] Confidential Page 50
Amended Protocol Version v02 Clean Protocol No. C AIN457F2304
Screening1Treatment Period 1 Treatment Period 2 / 3 (Primary  Treatment 
Period)
(Note: a patient enters Tx Period 3 in case 
of flare or when Tx Period 2 completes)Unscheduled 
visit Post -
Treatment 
Safety  
follow -up Notes
1 2
Week Up 
to 
-8-4 to 
BLBL 1 2 3 4 8 12/
PSW16 
to 
2024 28 
to 
4852 56 
to     
7276 80 
to 
100104 / 
TD/ 
PSW12 Weeks 
after last  
study  drug 
dosed
dose 
assignment
Vital signs: BP 
and pulseX X X X X X X X X X X X X X X X X X X
Quantiferon (or [COMPANY_003] 
skin test if required 
by [CONTACT_1295])XResults to be 
available prior 
to BL 
Hepatitis B, C and 
HIV serology3
(only in countries 
where it is required)SResults to be 
available prior 
to BL 
ECG X X X X X X
Contact [CONTACT_12067] S S S S S S S S S S S S S S S S S
Randomization via 
IRT XOnly 
responders will 
be randomized
Study Drug 
administration4,5
X X X X X X X5X5X5X5X5X5X5X5X5If flare 
confirmed at 
an 
unscheduled 
Tx Period 2 
visit, patient 
will receive Tx 
Period 3 OL 
secukinumab 
and continue to 
next scheduled 
visit

[COMPANY_001] Confidential Page 51
Amended Protocol Version v02 Clean Protocol No. C AIN457F2304
Screening1Treatment Period 1 Treatment Period 2 / 3 (Primary  Treatment 
Period)
(Note: a patient enters Tx Period 3 in case 
of flare or when Tx Period 2 completes)Unscheduled 
visit Post -
Treatment 
Safety  
follow -up Notes
1 2
Week Up 
to 
-8-4 to 
BLBL 1 2 3 4 8 12/
PSW16 
to 
2024 28 
to 
4852 56 
to     
7276 80 
to 
100104 / 
TD/ 
PSW12 Weeks 
after last  
study  drug 
dosed
PK sampling (pre -
dose)6 X X X X X X X X X X6X
Immunogenicity7X X X X X7X
Central laboratory 
Hematology/  Clinical 
Blood chemistry/ 
urinalysis (local)
X X X X X X X X X X X X X X XResults to be 
available prior 
to BL. If 
screening labs 
are <7 days 
prior to BL, 
then repeat
labs at BL are 
not necessary
Lipi[INVESTIGATOR_805]  (fasting) X X X X X
CRP (local lab)
X X X X X X X X X X X X X X X X XResults to be 
available prior 
to BL
Serum pregnancy 
test (for females of  X

[COMPANY_001] Confidential Page 52
Amended Protocol Version v02 Clean Protocol No. C AIN457F2304
Screening1Treatment Period 1 Treatment Period 2 / 3 (Primary  Treatment 
Period)
(Note: a patient enters Tx Period 3 in case 
of flare or when Tx Period 2 completes)Unscheduled 
visit Post -
Treatment 
Safety  
follow -up Notes
1 2
Week Up 
to 
-8-4 to 
BLBL 1 2 3 4 8 12/
PSW16 
to 
2024 28 
to 
4852 56 
to     
7276 80 
to 
100104 / 
TD/ 
PSW12 Weeks 
after last  
study  drug 
dosed
childbearing 
potential)
Urine pregnancy test 
(for females of 
childbearing 
potential) X X X X X XMay also be 
performed at 
the 
investigator’s 
discretion at 
any time during 
the study
AEs / SAEs (incl. 
injection site 
reaction)X X Update as necessary X X
Physician global 
assessment of 
disease activity 
(PGA) VAS10X X X X X X X X X X X X X X X X
CHAQ©
X X X X X X X X X X X X X X X XCHAQ©
includes the 
parent/patient’s 
global 
assessment of 
subject’s 
overall well -
being (VAS).
Active joint count
TJC/SJC
Joint count with 
limited range of X X X X X X X X X X X X X X X X

[COMPANY_001] Confidential Page 53
Amended Protocol Version v02 Clean Protocol No. C AIN457F2304
Screening1Treatment Period 1 Treatment Period 2 / 3 (Primary  Treatment 
Period)
(Note: a patient enters Tx Period 3 in case 
of flare or when Tx Period 2 completes)Unscheduled 
visit Post -
Treatment 
Safety  
follow -up Notes
1 2
Week Up 
to 
-8-4 to 
BLBL 1 2 3 4 8 12/
PSW16 
to 
2024 28 
to 
4852 56 
to     
7276 80 
to 
100104 / 
TD/ 
PSW12 Weeks 
after last  
study  drug 
dosed
motion
Tot. Dactylitis count X X X X X X X X X X X X X X X X
Tot. Enthesitis count X X X X X X X X X X X X X X X X
Assessment of 
UveitisX X X X X X X X X X X X X X X X

[COMPANY_001] Confidential Page 54
Amended Protocol Version v02 Clean Protocol No. C AIN457F2304
Screening1Treatment Period 1 Treatment Period 2 / 3 (Primary  Treatment 
Period)
(Note: a patient enters Tx Period 3 in case 
of flare or when Tx Period 2 completes)Unscheduled 
visit Post -
Treatment 
Safety  
follow -up Notes
1 2
Week Up 
to 
-8-4 to 
BLBL 1 2 3 4 8 12/
PSW16 
to 
2024 28 
to 
4852 56 
to     
7276 80 
to 
100104 / 
TD/ 
PSW12 Weeks 
after last  
study  drug 
dosed
Treatment period 1 
completion formX
Treatment period 2 
completion formX X X X X X X X XTobe 
performed at 
the completion 
of Tx Period 2.
Study Treatment 
Completion formX
Follow -up period  
Completion formX
Scheduled visits in Treatment Periods 2 and 3 are every 4 weeks.
X = assessment to be recorded in clinical data base; S= assessment to be recorded in source documentation; 
BL= baseline; Tx= Treatment; TD= study treatment discontinuation; PSW = Premature subject withdrawal

[COMPANY_001] Confidential Page [ADDRESS_1134978] the study  completion page for the screening period, demographics, 
inclusion/exclusion, and serious adverse event (SAE) data collected. Adverse events that are 
not SAEs will be followed by [CONTACT_819450]. Subject 
may discontinue from the study  prior to first study  drug administration. These subjects are 
considered screening failures. All subjects who have signed informed consent and have 
received the first study  drug administration will have all AEs occurring after informed consent 
is signed recorded on the Adverse Event eCRF page. If a patient discontinued prior to 
Baseline IRT provider must be notified within 5 days and the reason for patient not being 
enrolled in Treatment Period 1 will be entered on the screening page disposition CRF page.
6.2 Patient demographics/other baseline characteristics
Subject 
demographic and baseline characteristic data to be collected on all subjects and 
recorded in the eCRFinclude:
Age, gender, race, ethnicity  and source of subject referral.
Relevant JPsA/ERA JI A and relevant medical history /current medical condition data until 
the start of study  treatment, such as date of diagnosis of JPsA / ERA, previou s JPsA / ERA 
therapi[INVESTIGATOR_014], cardiovascular medical history , smoking history , and surgical history  including 
sterilization for females, if applicable.
Whenever possible, diagnoses and not sy mptoms will be recorded.
Investigators will have the discretion to record abnormal test findings on the medical history 
CRF page whenever in their judgment, the test abnormality  occurred prior to the informed 
consent signature.
6.[ADDRESS_1134979] eCRF page.
Drugs administered prior to start of treatment and other drugs/procedures continuing or started 
during the study  treatment period will be entered in the Prior/Concomitant medications or 
Significant non- drug therapi[INVESTIGATOR_144924].
The study  treatment will be administered by  [CONTACT_819451] (except in case 
of healthcare disruption, such as the COVID -19 pandemic/epi[INVESTIGATOR_901] -refer to Section 5.5.4),
thus compliance is expected to be 100%, unless temporary  interruption is needed for safet y 
reasons as described in 
Section 5.5.[ADDRESS_1134980] measures used across JI A trials.
JIA ACR 30, 50, 70, 90 and 100 response criteria

[COMPANY_001] Confidential Page 57
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
Physician’s Global Assessment of disease activity  (VAS)
Parent’s/patient’s Global Assessment of subject’s overall well- being (VAS included 
within CHAQ©)
Childhood Health Assessment Questionnaire (CHAQ©)
Active joint count
Joint count with limited range of motion
CRP (local)
Inactive disease status
 
 
JADAS score
Total dact ylitis count
Total enthesitis count
 
All efficacy  assessments should be performed prior to administration of study  treatment. 
6.4.[ADDRESS_1134981] ACR paediatric Criteria (JIA ACR criteria) consist of 6 core components which will 
be assessed as scheduled in Table 6-1.  JIA ACR 30/50/70/90/100 are defined as 30%, 50%, 
70%, 90% and 100% improvement from baseline respectivel y in a minimum of three 
variables in the core set with no more than one variable worsening more than 30% as defined 
in the ACR criteria.
The 6 core set variables are summarized below:
Physician global assessment o f disease activity  on a 0 -100 mm VAS from 0 mm 
= no 
disease activity  to 100 mm = very  severe disease activity
Parent or patient’s (if appropriate in age) Global Assessment of Subject’s overall well -
being on a 0 -100 mm VAS from 0 mm = very well to 100 mm = very poor .
Functional ability : Childhood Health Assessment Questionnaire (CHAQ©) 
Number of active joints using the ACR definition (any joint with swelling or in the 
absence of swelling, limitation of motion accompanied b y either pain on motion or 
tend
erness not due to deformity )
Number of joints with limited range of motion
Laboratory measure of inflammation: CRP (mg/L )

[COMPANY_001] Confidential Page 58
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
The respective response variables listed above will be used by a central vendor to determine 
ACR Pediatric response, responder status at Week 12, and flare occurrence in Treatment 
Period 2. These results will be communicated to the investigator prior to the patient leaving 
the study  site. Additionally , these components will be used to determine JADAS and inactive 
disease status (Wallace et al. 2011) as part of secondary   analy ses. 
6.4.2 Physician’s Global A ssessment of disease activity (V AS)
The physician will rate the patient’s current condition on a 0-100 mm VAS (Appendix 5), 
ranging from no disease activity  (0 mm) to very severe disease activity  (100 mm), at each 
scheduled visit for all patients throughout the study .
Scores on the [ADDRESS_1134982] not be aware of the specific parent’s or patient’s 
global assessment of patient’s overall well-being, when performing his own assessment on 
that patient.
6.4.3 Parent’s/patie nt’s Global A ssessment of subject’s overall well -being 
(VAS)
The parent’s or patient’s global assessment of the patient’s overall well -being will be assessed 
on the VAS that is part of the CHAQ©. The VAS scale ranges from 0 -100 mm, from very  well 
(0 mm) to very poor (100 mm). 
Scores on the [ADDRESS_1134983] millimeter from the left.
6.4.4 Childhood Health A ssessment Questionnaire (CHA QCopy right)
The Childhood Health Assessment Questionnaire, CHAQ©(Appendix 6),will be used to 
assess phy sical ability  and functional status of patients as well as quality  of life. The disabilit y 
dimension 
consists of multiple choice and VAS items concerning difficulty  in performing 
eight common a ctivities of daily  living; dressing and grooming, arising, eating, walking, 
reaching, personal hygiene, grippi[INVESTIGATOR_144933]. Subjects choose from four response 
categories, ranging from ‘without any  difficulty ’ to ‘unable to do’. 
This questionnaire sho
uld be completed by [CONTACT_7071] (or, for patients 18 years and older, the 
questionnaire will be completed together by  [CONTACT_786963]) according to schedule 
in Table 6-1. The CHAQ©will be completed only in a validated version of the instrument in 
the language understandable to the parent and/or patient.
Completed 
questionnaires will be reviewed and examined by [CONTACT_093], before the 
clinical examination, for responses which may indicate potential AEs or SAEs. If AEs or 
SAEs are confirmed, then the physician must record the events as per instructions given in 
Section 7.1 and Section 7.2of the protocol. Investig ators should not encourage the patients 
and/or parents to change the responses reported in the PRO questionnaires.
6.4.5 Active joint count
The number of joints with active arthritis at each visit will determined by [CONTACT_819452], tenderness and limited range of motion at 

[COMPANY_001] Confidential Page 59
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
each scheduled visit for all patients throughout the study  (see Section 6.4.6 and Section 6.4.8
for more detail).
Joint counts will be performed by [CONTACT_819453]. For there to be consistency  between the joint assessments, it is strongl y 
recommended that the same evaluator perform these assessments at all visits.
The ACR definition of active arthritis is any  joint with swelling or, in the absence of swelling, 
limitation of motion accompanied by  [CONTACT_786962] .  
The active joint count will therefore range from 0 to 73.
6.4.6 Joint counts with limitation of motion
A total of 69 joints will be assessed for limitation of motion at each scheduled visit for all 
patients throughout the study .  The same 75 joints assessed for tenderness 
(Section 6.4.8) will 
also be assessed for limitation of motion excluding the 2 stern
oclavicular, 2 acromioclavicular 
joints as well as the 2 sacroiliac joints. 
For there to be consistency  between the joint assessments, it is strongly  recommended that the 
same evaluator perform these assessments at all visits.
6.4.7 C-reactive Protein (CRP) 
C-reactive Protein (CRP) will be determined at each scheduled visit for all patients throughout 
the study  and during unscheduled visits wh ere efficacy  is assessed.
CRP is used as an inflammation marker, to determine its severity , and to monitor response to 
treatment.
CRP (mg/L) will be measured at the local lab, including during unscheduled visit for flares, 
and t he actual sample collection date, time and result will be collected. 
6.4.8 Tender and Swollen Joint Count 
Tender 75 joint count (TJC)
The following 75 joints will be scored as either tender or not tender:   
Temporomandibular joints: 2 
Sternoclavicular joints : 2 
Acromioclavicular joints : 2 
Shoulders : 2 
Elbows : 2 
Wrists : 2
Hands : 
distal interphalangeal 
10 proximal interphalangeal 
10 metacarpophalangeal  
Hip: 2 

[COMPANY_001] Confidential Page 61
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
Anterior Entheses : Greater trochanter of the Femur; Medial condy le of the femur; Lateral 
condy le of the femur
Posterior E ntheses: Greater tuberosit y of humerus; medial epi[INVESTIGATOR_819423]; lateral 
epi[INVESTIGATOR_819423], Achilles tendon; and calcaneal insertion of the plantar fascia.

[COMPANY_001] Confidential Page 62
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304

[COMPANY_001] Confidential Page 63
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
6.4.20 Juvenile A rthritis Disease A ctivity  Score (JA DAS)
Juvenile Arthritis Disease Activity  Score (JADAS) (Consolaro et al. 2009 ) will be derived 
from the following assessments performed at all scheduled visits:
physician global assessment of disease activity ; 
parent /patient global assessment of overall well -being; 
active joint count; 
CRP (local)

[COMPANY_001] Confidential Page [ADDRESS_1134984] be met:
No joints with active arthritis 
No uveitis
CRP value within normal limits f or the laboratory where tested or, if elevated, not 
attributable to JIA
Physician’s global assessment of disease activity  score ≤ 1 0mm
Duration of morning stiffness attributable to J IA  ≤15 min
6.5 Safet y 
Evaluation of all AEs and SAEs including injection site reactions, abnormal findings in ECGs, 
physical examination, 
vital signs, and laboratory assessments will occur. Anti- secukinumab 
antibody  development (immunogenicit y) will also be evaluated.
All blood draws and safet y assessments should be done prior to study  treatment 
administration. Appropriate safet y assessments (e.g.,evaluation of AEs and SAEs including 
injection site reactions) should be repeated after the dose is administered.
Evaluation of AE/ SAEs
Physical examination
Vital signs
Height and weight
QuantiFERON TB- Gold test (or [COMPANY_003] skin test if < 5 years of age or required by  [CONTACT_21482])
Hepatitis B, Hepatitis C and HIV serology  (screening for patients who require it by  [CONTACT_21482]) 

[COMPANY_001] Confidential Page 65
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
Electrocardiogram
Laboratory evaluations (Hematology , Clinical Chemistry , Lipid Panel, Urinaly sis)
Pregna ncy and assessment of fertility
Tolerability  of secukinumab 
Immunogenicit y
6.5.[ADDRESS_1134985] in sitting 
position. If possible, vital signs assessments should be performed by [CONTACT_819454] .
Clinically  notable vital signs are defined in Appendix 1 .
6.5.3 Height and weight 
Height in centimeters (cm) will be assessed with the patient wearing indoor clothing, but 
without shoes, socks, hats or hair accessories interfering with assessment , using a stadiometer 
that is calibrated on a regular basis. Height measurements will be performed twice and the 
reported height will be the mean of the 2 measurements .  
Body weight (to the nearest 0.1 kilogram (kg) will be assessed with the patient wearing 
similar clothing (indoor clothing but without shoes) at each visit and where possible, by [CONTACT_819455] .
6.5.[ADDRESS_1134986] (or a [COMPANY_003] skin test if patient < 5 years of age or required by
[CONTACT_427]) must be performed at either Screening visit [ADDRESS_1134987]’s eligibility  for the trial. The QuantiFERON 
TB-Gold test will be performed by  [CONTACT_2237] . Detail s on the collection, processing 
and shipment of samples and reporting of results by [CONTACT_811507].
If a [COMPANY_003] skin test is required based on age or local regulations, it can be performed at either 
Screening visit [ADDRESS_1134988]’s eligibility  for 
the trial. The test dose is bioequivalent to [ADDRESS_1134989] superficial layer under the skin. If given correctl y, the 
injection should raise a small wheal of about 5 mm, which resolves within 10 -15 minutes. 
Because the reaction (induration) will take [ADDRESS_1134990]. A reaction is measured in 
millimeters of induration (hard swelling) at the site. A [COMPANY_003] skin induration ≥ 15 mm for 
children ≥ 4 years and ≥ 10 mm for children < 4 years of age (or according to local 
practice/guidelines) is interpreted as a positive result.
Subjects with a positive test (QuantiFERON TB -Gold test or [COMPANY_003] skin test) may participate in 
the study  if (1) active TB is ruled out and (2) the patient is willing and able to complete a 
minimum of 4 weeks of latent TB treatment prior to initiating treatme nt with secukinumab 
and (3) the patient is willing to continue and complete the latent TB treatment (according to 
local guidelines) in parallel with study  treatments.  In the absence of local guidelines the US 
CDC guidelines for treatment of latent TB must be followed i.e. INH treatment for 9 months. 
Patients diagnosed with active TB should be referred for treatment as deemed appropriate and 
are not eligible to participate in this study .  
6.5.5 Laboratory  evaluations
A central laboratory  will be used for analysis of all specimens listed below (except dipstick 
urinaly sis and CRP which are done locally ). Details on the collection, processing and 
shipment of samples, and reporting of results by [CONTACT_811507]. For the identification of clinically  notable values, see Appendix 1. All 
subjects with laboratory tests containing clinically  significant abnormal values are to be 
followed until the values return to normal ranges or until a valid reason, other than treatment 
related AE, is defined.
[IP_ADDRESS] Hematology
Hemoglobin, platelets, red blood cell (RBC), white blood cell (WBC) and differential white 
blood cell counts will be measured at scheduled visits as per Table 6
-1.
[IP_ADDRESS] Clinical chemistry
Serum chemistries will include glucose, urea, creatinine, total bilirubin, AST (SGOT), ALT 
(SGPT), GGT (Gamma -glutam yl transferase ), alkaline phosphatase, sodium, potassium, 
bicarbonate, calcium , phosphorus, total protein, albumin and uric acid will be measured at 
scheduled visits as per Assessment Schedule in Table 6-1.
[IP_ADDRESS] Urinaly sis 
Dipsticks will be provided by [CONTACT_819456] 6-1. The urinal ysis results for standard 
parameters such as protein, glucose, blood and WBCs will be recorded in the appropriate 
eCRF page.

[COMPANY_001] Confidential Page 67
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
If the dipstick result is positive for protein, glucosuria and/or blood, a urine sample will be 
sent to central laboratory  for microscopic analysis as indicated in the renal safet y section 
(Section 7.4). 
[IP_ADDRESS] Lipid panel
A lipid profile including High Density  Lipoprotein (HDL), Low Density  Lipoprotein (LDL), 
total cholesterol, and trigly cerides will be measured from a fasting blood sample that will be 
collected at Baseline and at visits indicated in Table 6
-1.
6.5.6 Electrocardiogram (ECG) 
A standard 12-lead ECG will be performed as indicated inTable 6-1. All ECGs must be 
performed on the ECG machines provided for the study . ECGs must be recorded after [ADDRESS_1134991] in the supi[INVESTIGATOR_188597] a stable baseline. The preferred sequence of 
cardiovascular data collection during study  visits is ECG collection followed by [CONTACT_819457]. The Frider icia QT correction formula (QTcF) should be used for clinical 
decisions.
All ECGs will be centrally  and independently  reviewed. Instructions for the collection and 
transmission of the ECGs to the independent reviewer will be provided in the ECG 
Investigato
r manual.
Each ECG tracing should be labeled with study  number, subject initials, subject number, date 
and time, and filed in the study  site source documents. For any ECGs with subject safet y 
concerns, two additional ECGs should be performed to confirm thesafety  finding. Clinicall y 
significant ECG findings at baseline must be discussed with the sponsor before administration 
of investigational treatment. Clinically  significant abnormalities should be recorded on the 
relevant section of the medical history /Current medical conditions eCRF page as appropriate.  
6.5.[ADDRESS_1134992] will be performed in all women of childbearing potential at Screening 
visit 2.  Urine pregnancy tests are performed at Baseline and at visits indicated in Table 6 -1in 
all female subjects of childbearing potential. Additional pregnancy  tests may be performed at 
the investigator’s discretion during the study . A positive urine pregnancy  test requires 
immediate interruption of study  treatment until serum β-hCG is performed and found to be 
negative. If positive, the subject must be discontinued from stud y drug. 
All menarchal girls and their parents/caregivers should be informed about the potential 
risks 
of pregnancy  and the need to prevent pregnancy  during the stud y. 
It is important to be sensitive in introducing this issue, as understanding and comprehension 
of pubert y, sexual activity , pregnancy  and contraception is influenced by [CONTACT_654], as well as 
factors such as precocity , socio(educational) economic and familial background. These 
discussions with the patient and her parents/caregivers are therefore best performed by 

[CONTACT_18619] [ADDRESS_1134993] results 
with the patient and her parent s/caregivers. The privacy  of the adolescent should be 
considered in accordance with the local law and ethics.
Female patients of child- bearing potential, who are or might become sexually  active, must be 
informed of the need to prevent pregnancy  during the study  and for 20 weeks after study 
completion. At a minimum, the acceptable effective contraception is:
Abstinence
Barrier method: Condom or Occlusive cap (diaphragm or cervical/vault caps). For [LOCATION_006] 
([LOCATION_008]): with spermicidal foam/gel/film/cream/vag inal suppository
Use of established oral, injected or implanted hormonal methods of contraception , 
intrauterine device (IUD) or intrauterine s ystem (IUS)
The decision on the contraceptive method should be reviewed at least every  3 months to 
evaluate the individual need and compatibility of the method chosen and the need for 
additional pregnancy  testing.
6.5.8 Tolerability  of secukinumab
Tolerability  will be assessed by [CONTACT_20721], laboratory  values, injection site reactions and 
immunogenicit y.
6.5.9 Immunogenicit y
Blood samples for immunogenicity  (anti-AIN457 antibodies) will be taken pre-dose at the 
scheduled time points as indicated in Table 6-1. 
In addition, if a subject discontinues from the study  at any time, he/she will need to provide a 
sample at the last visit. The actual sample collection date and exact time will be entered on the 
Immunogenicit y Blood collection eCRF page. Sampling problems will be noted in the 
Comment section of the eCRF page.
All bloo d samples will be taken by [CONTACT_553531] a forearm vein.
A laboratory  manual will be provided to investigators with detailed information on sample 
collection, handling and shipment.
Tubes and preprinted lab els will be provided b y the central lab to the sites. 
Analytical Method
An electrochemiluminescence method will be used for the detection of potential anti-
secukinumab antibody  formation. The detailed method description to assess immunogenicit y 
will be described in the bioanalytical raw data of the study  and in the respective Bioanal ytical 
Data Report. 

[COMPANY_001] Confidential Page 69
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
Table 6-4 IG sample log
Week IG Sample log
0 301
12 302
52 303
104 304
112 305
If an IG sample is collected at an unscheduled visit, the sample numbers will follow the 
pattern: 3001, 3002, etc
6.5.[ADDRESS_1134994] for a use of a biologic in patients with 
JPsA / ERA and are standard and adequate for this indication/subject population. Quantiferon 
or [COMPANY_003] testing at screening is performed to rule out the presence of active tuberculosis. The 
frequency  of the visits and the close medical monitoring will ensure possible safety  concerns 
are properl y addressed.
6.6 Other assessments
6.6.1 Resource utilization 
No measures of Healthcare Resource Utilization (RU) will be collected in the study .
6.6.2 Pharmacokinetics 
PK samples will be obtained for all subjects and the secuk inumab concentrations will be 
assessed in serum. The PK samples will be collected pre-dose at scheduled visits/ time points 
as indicated in Table [ADDRESS_1134995] will provide the samples’ concentration data to the team under 
blinded conditions. Bioanaly st will keep this information confidential until clinical database 
lock.
PK sample handling, labeling and shipment instructions
Laboratory  manuals will be provided by [CONTACT_37274], sample handling and shipment.
Tubes and labels will be provided by [CONTACT_144969] /sample type 
information pre -
printed on the label .

[COMPANY_001] Confidential Page 70
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
PK samples should be collected at treatment Period 2 visits where a disease flare is confirmed.  
If a flare is confirmed at an unscheduled visit, the sample number will be 1001 as described in
Table 6-5.
Table 6-5 PK sample log 
Week Time Sample number Dose reference ID
0 1pre-dose 10 1
2 1pre-dose 20 1
4 1pre-dose 30 1
8 1pre-dose 40 1
12 1pre-dose 50 1
16 2pre-dose 51 1
20 2pre-dose 52 1
24 1pre-dose 60 1
28 2pre-dose 61 1
32 2pre-dose 62 1
36 2pre-dose 63 1
40 2pre-dose 64 1
44 2pre-dose 65 1
48 2pre-dose 66 1
52 1pre-dose 70 1
56 2pre-dose 71 1
60 2pre-dose 72 1
64 2pre-dose 73 1
68 2pre-dose 74 1
72 2pre-dose 75 1
76 1pre-dose 80 1
80 2pre-dose 81 1
84 2pre-dose 82 1
88 2pre-dose 83 1
92 2pre-dose 84 1
96 2pre-dose 85 1
100 2pre-dose 86 1
104 1,3672h (Any time at visit) 90 2
112 1,[ZIP_CODE] h (Any time at visit) [ADDRESS_1134996] dose given at W eek 100
4.Sample collected for subjects with confirmed flare in Treatment Period 2 occurring at an 
unscheduled visit.
If a PK sample is collected at an unscheduled visit, the sample numbers will follow the pattern: 
1001, 1002, etc.

[COMPANY_001] Confidential Page 72
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
7 Safety  monitoring
7.1 Adverse events 
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and 
unintended sign, including abnormal laboratory  findings, symptom or disease) in a subject or 
clinical investigation subject after providing written informed consent for participation in the 
study  until the end of study  visit. Therefore, an AE may or may not be temporally  or causall y 
associated with the use of a medicinal (investigational) product.
In addition, all reports of intentional misuse and abuse of the product are also considered an 
adverse event irrespective if a clinical event has occurred.
The occurrence of adverse events must be sought by [CONTACT_105]-directive questioning of the patient 
at each visit during the study . Adverse events also may  be detected when they  are volu nteered 
by [CONTACT_105267], laboratory 
test findings, or other assessments.
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the followin g criteria:
they induce clinical signs or sy mptoms, 
they are considered clinically
 significant, 
they require therapy . 
Clinically  significant abnormal laboratory  values or test results must be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
Baseline or the previous visit, or values which are considered to b e non-typi[INVESTIGATOR_18532]. Investigators have the responsibility  for managing the safet y of individual 
patient and identify ing adverse events. Alert ranges for laboratory  and other test abnormalities 
are included in Appendix [ADDRESS_1134997] be recorded in the Adverse Events CRF page under the signs, sy mptoms 
or diagnosis associated with them, accompanied by [CONTACT_6644]:
the severit y grade
mild: usually  transient in nature and generally  not interfering with normal activities
moderate: sufficiently  discomforting to interfere with normal activities
severe: prevents normal activities
its relationship to the study  treatment (no/ yes), or other treatment (no/ yes), or both, or 
indistinguishable

[COMPANY_001] Confidential Page 73
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
its duration (start and end dates) or if the event is ongoing an outcome of not 
recovered/not resolved must be reported.
whether it constitutes a serious adverse event (see Section 7.2.1 for d efinition of SAE)
action taken regarding investigational treatment 
All adverse events must be treated appropriately . Treatment may include one or more of the 
following: 
no action taken (e.g. further observation only ) 
investigational treatment dosage adjusted/temporarily  interrupted 
investigational treatment permanentl y discontinued due to this adverse event 
concomitant medication given 
non-drug therap y given 
patient hospi[INVESTIGATOR_057]/patient’s hospi[INVESTIGATOR_18533] (see Section 7.2.1 for definition of 
SAE)
its outcome (not recovered/not resolved; recovered/resolved; recovering/resolving, 
recovered/resolved with sequelae; fatal; or unknown)
Once an adverse event is detected, it must be followed until its resolution or until it is judged 
to be permanent, and assessment must be made at each visit (or more frequently , if necessary ) 
of any changes in severity , the suspected relationship to the study  drug, the interventions 
required to treat it, and the outcome .
Information 
about common side effects alread y known about the investigational drug can be 
found in the Investigator Brochure (IB). This information will be included in the patient 
informed consent and should be discussed with the patient/guardian during the study  as 
needed. Any new information regarding the safety  profile of the medicinal product that is 
identified between IB updates will be communicated as appropriate, for example, via an 
Investigator Notification or an Aggregate Safet y Finding. New information might require an 
update to the informed consent and has then to be discussed with the patient/guardian.
The Investigator must also instruct each patient/guardian to report any new adverse event 
(beyond the protocol observation period) that the patient/guardian, or the patient’s personal 
physician, believes might reasonabl y be related to study  treatment. This information must be 
recorded in the investigator’s source documents; however, if the AE meets the criteria of an 
SAE, it must be reported to No vartis.
7.2 Serious adverse events 
7.2.1 Definition of SA E 
An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)] 
undesirable sign(s), symptom(s) or medical conditions(s)) which meets any one of the 
following criteria:
is fatal or life -threatening 
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect

[COMPANY_001] Confidential Page 74
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
requires inpatient hospi[INVESTIGATOR_1081], unless 
hospi[INVESTIGATOR_062]:
routine tr eatment or monitoring of the studied indication, not associated with any  
deterioration in condition (specify  what this includes)
elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not wors ened since signing the informed consent
treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063] 
social reasons and respi[INVESTIGATOR_5316]’s 
general condition
is medically  significant, e.g. defined as an event that jeopardizes the patient or may  
require medical or surgical intervention.
All malignant neoplasms will be assessed as serious under “medically  significant” ifother 
seriousness criteria are not met.
Life-threatening in the context of a SAE refers to a reaction in which the patient was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused death if it were more severe (see Annex IV, International Conference on 
Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human 
Use (ICH) -E2D Guideline).
Medical and scientific judgment should be exercised in deciding whether other situat ions 
should be considered serious reactions, such as important medical events that might not be 
immediately  life threatening or result in death or hospi[INVESTIGATOR_105195]. 
Examples of such events are intensive treatment in an emergency  room or at home for allergic 
bronchospasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_395130] (see Annex IV, ICH-E 2D Guideline).
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
7.2.[ADDRESS_1134998] has stopped study participation (whichever is later) must be 
reported to [COMPANY_001] within [ADDRESS_1134999] be reported separatel y as a new event.

[COMPANY_001] Confidential Page 75
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The Investigator must assess the relationship of each SAE to the study  
treatment, complete the SAE Report Form in English, and submit the completed form within 
[ADDRESS_1135000] be reported as a follow -up 
to that event regardless of when it occurs. The follow -up information should describe whether 
the event has resolved or continues, if and how it was treated, whether the blind was broken or 
not, and whether the patient continued or withdrew from study participation.
If the SAE is not previously  documented in the Investigator’s Brochure or Package Insert 
(new occurrence) and is thought to be related to the study  treatment a Drug Safet y and 
Epi[INVESTIGATOR_819424]. [COMPANY_001] may need to issue an Investigator 
Notification (IN) to inform all investigators involved in any study with the same study  
treatment that this SAE has been reported. Suspected Unexpected Serious Adverse Reactions 
(S[LOCATION_003]Rs) will be collected and reported to the competent authorities and relevant ethics 
committees in accordance with EU Guidance 2011/C 172/01 or as per national regulatory 
requirements in participating countries.
7.3 Liver safety  monitoring 
To ensure patient safet y and enhance reliab ility in determining the hepatotoxic potential of an 
investigational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be followed. 
The following two categories of abnormalities / adverse events have to be considered during 
the course of the study  (irrespective of whether classified/reported as (S)AE):
Liver laboratory  triggers, which will require repeated assessments of the abnormal 
laboratory  parameter
Liver events, which will require close observation, follow -up monitoring and completion 
of the standard base liver CRF pages
Please refer to Table 14-1 in Appendix 2for complete definitions of liver laboratory  triggers 
and liver events. 
Every  liver laboratory  trigger or liver event as defined in Table 14-1 ofAppendix 2should be 
followed up by [CONTACT_18657]. 
Detailed information is outlined in Table 14
-1in Appendix 2 .
For the l iver laboratory  trigger:
Repeating the liver function test (LFT) within the next week to confirm elevation.
These LFT repeats must be performed using the central laboratory  if possible. If this is not 
possible, then the repeats can be performed at a local laboratory  to monitor the safet y of the 
patient. Repeats laboratory  must then be performed at central laboratory  as soon as possible. If 

[COMPANY_001] Confidential Page [ADDRESS_1135001] be reported on the Liver CRF pages.
If the elevation is confirmed, close observation of the patient will be initiated, including 
consideration of treatment interruption if deemed appropriate.
For the liver events:
Repeating the LFT to confirm elevation as ap propriate
Discontinuation of the investigational drug if appropriate
Hospi[INVESTIGATOR_18539]
A causalit y assessment of the liver event via exclusion of alternative causes (e.g., disease, 
co-medications)
An investigation of the liver e vent which needs to be followed until resolution. 
These investigations can include serology  tests, imaging and pathology  assessments, 
hepatologist’s consultancy , based on investigator’s discretion. All follow -up information, and 
the procedures performed must be recorded on appropriate CRF pages, including the liver 
event overview CRF pages.
7.[ADDRESS_1135002] to be considered 
during the course of the study :
Serum event:
confirmed (after ≥24h) increase in serum creatinine of ≥25% compared to baseline 
which exceeds the normal limits for the patient’s gender and age during normal 
hydration status and continues for ≥ 3 consecutive months.
Urine event
new onset ( ≥1+) proteinuria; confirmed b y doubling in the urinary  albumin -creatinine 
ratio (ACR) or urinary  protein -creatinine ratio (PCR) (if applicable)
new onset ( ≥1+), hematuria or gl ycosuria 
Every  renal laboratory  trigger or renal event as defined in Table 15 -1in Appendix 3 should be 
followed up by [CONTACT_819458] 3 .
7.5 Reporting of study  treatment errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, patient or
consumer (EMA definition).
Misuse refers to situations where the medicinal product is intentionally  and inappropriatel y 
used not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal 
product, which is accompanied by  [CONTACT_50104].

[COMPANY_001] Confidential Page 77
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
Study  treatment errors and uses outside of what is foreseen in the protocol will be collected in 
the DAR (dose administration record) eCRF page irrespective of whether or not associat ed 
with an AE/SAE and reported to Safety  only if associated with an SAE. Misuse or abuse will 
be collected and reported in the safety  database irrespective of it being associated with an 
AE/SAE.
Table 7-1 Treatment Errors
Treatment error 
typeDocument in Dose 
Administration 
(DAR) eCRF (Yes/No)Document in A E 
eCRFComplete SA E form
Unintentional study 
treatment errorYes Only if associated with 
an AEOnly if associated with an
SAE
Misuse/Abuse Yes Yes, Yes, even if not 
associated with a SAE
7.[ADDRESS_1135003] be 
reported to [COMPANY_001] within 24 hours of learning of its occurrence. Where possible, the 
pregnancy  should be followed up to determine outcome, including spontaneous or voluntar y 
termination, details of the birth, and the presence or absence of any birth defects, congenital 
abnormalities, or maternal and/or newborn complications.
Where possible, pregnancy  must be recorded on the Pharmacovigilance Pregnancy  Form and 
reported by [CONTACT_819459] y and Epi[INVESTIGATOR_18540]. 
Pregnancy  follow -
up should be recorded on the same form and should include an assessment 
of the possible relationship to the study  treatment. 
Any SAE experienced during the pregnancy  and unrelated to the pregnancy  must be reported 
on a SAE form.
8 Data revie w and database management
8.1 Site monitoring 
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] 
representative will review the protocol and data capture requirements (i.e. eCRFs ) with the 
investigators and their staff. During the study , [COMPANY_001] employ s several methods of ensurin g 
protocol and Good Clinical Practice (GCP) compliance and the quality /integrity  of the sites’ 
data. The field monitor will visit the site to check the completeness of patient records, the 
accuracy  of data capture / data entry , the adherence to the protocol and to Good Clinical 
Practice, the progress of enrollment, and to ensure that study  treatment is being stored, 
dispensed, and accounted for according to specifications. Key study personnel must be 
available to assist the field monitor during these visits.  Cont inuous remote monitoring of each 
site’s data may be performed by a centralized [COMPANY_001] CRA organization. Additionally , a 
central analytics organization may analyze data & identify  risks & trends for site operational 
parameters, and provide reports to Nova rtis Clinical Teams to assist with trial oversight.

[COMPANY_001] Confidential Page [ADDRESS_1135004] maintain source documents for each patient in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, labor atory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
patient's file. The Investigator must also keep the original informed consent form signed by 
[CONTACT_102]/guardian (a signed cop y is given to the patient/guardian).
The Investigator must give the monitor access to all relevant source documents to confirm 
their consistency  with the data capture and/or data entry . [COMPANY_001] monitoring standards 
require full verification for the presence of informed consent, adherence to the 
inclusion/exclusion criteria, documentation of SAEs, and of data that will be used for all 
primary  variables. Additional checks of the consistency  of the source data with the CRFs are 
performed according to the study -specific monitoring plan. No information in source 
documents about the identity  of the patients will be disclosed.
8.2 Data collection 
Designated investigator staff will enter the data required by [CONTACT_109051]/RDC 
system. Designated investigator site staff will not be given access to the system until they 
have been trained.
Automatic validation procedures within the system check for data discrepancies during and 
after data entry  and, by [CONTACT_105273], allow the data to be confirmed 
or corrected online by [CONTACT_105274]. The Investigator must certify  that 
the data entered into the electronic Case Report Forms are complete and accurate. After 
database lock, the investigat or will receive copi[INVESTIGATOR_105196].
Adapted ACR Pediatric response and disease flare occurrence will be determined centrall y 
from data (ACR components) provided by [CONTACT_093].  These will be derived and 
communicated to the investigator the same day.
8.[ADDRESS_1135005] the data.
Concomitant medications entered into the database will be coded using the World Health 
Organization (WHO) Drug Reference List, which employ s the Anatomical Therapeutic 
Chemical classification system. Concomitant procedures, non-drug therapi[INVESTIGATOR_18541] (MedDRA) 
terminology .
Laboratory  samples (except for CRP) will be processed centrally  and the results will be sent 
electronically  to [COMPANY_001] (or a designated CRO).

[COMPANY_001] Confidential Page 80
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
9 Data analy sis 
A general description of the statistical methods to be used to analyze the efficacy  and safet y 
data is outlined below. Specific details will be provided in the Statistical Analy sis Plan.
This trial is conducted as a three -part study . Data summaries may be presented separatel y for 
each stud y part and for combined study  parts where appropriate. 
Unless otherwise stated, all statistical tests will be two-sided at the 5% significance level and 
accompanied b y two -sided 95% conf idence intervals where appropriate.
Any data analy sis carried out independently  by [CONTACT_819460].
The trial follow sthe recommendation of the Consolidated Standards of Reporting Trials 
(CONSORT) statement and results are reported for the intention -to-treat population (Schulz et 
al 2010) .
9.1 Analysis sets 
The following anal ysis sets will be used in this trial:
The randomized set will be defined as all subjects who were randomized in Treatment Period 
2. Unless otherwise specified, mis-
randomized subjects (mis-randomized in IRT) will be 
excluded from the randomized set.
Mis- randomi zed subjects are defined as those subjects who were mistakenly  randomized into 
the IRT prior to the site confirming all eligibility  criteria had been met and to whom no study 
medication was given in Treatment Period 2.
The Full Anal ysis Set (FAS) Treatment Period [ADDRESS_1135006] deviation, median, minimum, maximum, 25% 
and 75% quantiles, and number of patients with non-missing data. Categorical variables will 
be summarized by  [CONTACT_819461]. 
Comparability  of treatment groups in Treatment Peri od [ADDRESS_1135007] to the demographic and 
baseline characteristics will be assessed descriptively .
Relevant medical history/current medical conditions will be listed and summarized by [CONTACT_268318] .
9.3 Treatment
s 
Study treatment
The exposure to study  drug (number of injections) and duration of exposure (days) will be 
summarized and listed.
The number and percentage of patients taking medication and non-drug therapi[INVESTIGATOR_819425] g to the WHO Drug Reference List dictionary  (which 
employ s the Anatomical Therapeutic Chemical classification system). Separate summaries 
will be provided for therapi[INVESTIGATOR_819426] 1 (prior therapi[INVESTIGATOR_014]) and 
were active after the star t of Treatment Period 1 (concomitant therapi[INVESTIGATOR_014]).
The FAS corresponding to the study  periods summarized will be used.
9.4 Analysis of the primary  variable(s)
9.4.1 Variable(s)
The primary  efficacy  endpoint will be time to disease flare event in Treatment Period 2, wh ich 
is defined as the 
interval between the date of randomization to the date of first occurrence of 
disease flare event. The analysis of the primary  efficacy  endpoint will be based on the FAS 
Treatment Period 2.
All subjects who enter Treatment Period [ADDRESS_1135008] not experienced flare event at the end of Treatment Period 2 data 
(as defined in Section 3.1) or discontinue prematurel y from Treatment Period [ADDRESS_1135009] efficacy  evaluation in Treatment Period 2.
Statistical mod el, hypothesis, and method of analysis
The primary  objective for Treatment Period 2 of the study  is to show superiorit y of 
secukinumab over placebo regarding the primary  variable in Treatment Period 2.

[COMPANY_001] Confidential Page 82
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
The following statistical hy pothesis will be tested on ce the required number of flares has been 
observed and the study  has been stopped:
H0: 1-SAIN(t) ≥ 1- SPla(t) 
HA: 1-SAIN(t) < 1 - SPla(t)
at each time point t, with SAIN(t) and SPla(t) being the survivor functions in the secukinumab 
and placebo treatment group at time t.
The two treatment groups will be compared using a one-sided stratified Logrank test with the
stratification factor of JIA category  (ERA or JPsA) at the 2.5% level of significance. Hazard 
ratios and their associated 95% confidence intervals will be estimated based on a Cox 
proportional hazards model with treatment and stratification factor as explanatory  variables.
The Kaplan -Meier estimates of the proportion of patients with the flare event at selected 
landmark points, along with its 95% co nfidence intervals using Greenwood’s formula, will be 
provided. The primary  analy sis will be based on the FAS for Treatment Period 2.
Handling of missing values/censoring/discontinuations
All patients in Treatment Period [ADDRESS_1135010].
The primary  analysis will be repeated where patients discontinuing the study for any reason 
will be considered as having flare at the time of study discontinuation.
Subgroup anal yses for the primary  efficacy  variable will be performed for stratification factor: 
JIA category  (ERA or JPsA).
Analysis of secondary variables
9.4.[ADDRESS_1135011] deviation, 
minimum, median, maximum, 25% and 75% quantiles, and numbe r of patients with non-
missing data. For binary or discrete 
variables the number of subjects in each category  and 
relative frequencies will be provided.
The following secondary  efficacy  endpoints will be analyzed for all patients and each JIA 
category  by [CONTACT_819462] 1:
JIA ACR 30/50/70/90/100 and inactive disease status 
Each J IA ACR core component 
Change from baseline Juvenile Arthritis Disease Activity  Score (JADAS) score
Total enthesitis count
Total dact ylitis count

[COMPANY_001] Confidential Page 83
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
The following secondary  efficacy  endpoints will be analyzed for all patients and each JIA 
category  by [CONTACT_819462] 2, and/or other periods, as appropriate:
JIA ACR 30/50/70/90/[ADDRESS_1135012]-
baseline safet y assessment. All data will be analy zed according to the treatment actuall y 
received.
The safet y variables to be analy zed include Adverse events (AEs), clinical laboratory  tests 
(hematology  and chemistry ), phy sical examination results, ECGs, and deaths. Safet y variables 
are to be tabulated by [CONTACT_9086] (n, mean, median, standard deviation, minimum, 
and maximum; or n and percent). No formal statistical testing is planned.
[IP_ADDRESS] Adverse events
Adverse events will be coded using the MedDRA dictionary  that provides the primary  system 
organ class and preferred term information. Adverse events will be presented in two parts:
Adverse events (including infections)
Infectious adverse events
Adverse events will be summarized by [CONTACT_1601], for each study  period and each treatment 
group, the number and percentage of patients having any adverse event, having any adverse 
event in each primary  system organ class and having each individual adverse event based on 
the preferred term. All other information collected (e.g. severity , relationship to study  drug) 
will be tabulated and listed as appropriate. 
Deaths, serious adverse events, and adverse events leading to discontinuation of study  drug 
will be summarized by  [CONTACT_819463].
[IP_ADDRESS] Vital signs 
Vital signs data will be summarized by  [CONTACT_819464]. All information collected will be listed by [CONTACT_819465] (see Appendix 1 ) will be flagged.
[IP_ADDRESS] Laboratory  evaluations
Laboratory  data will be summarized in the same way as vital signs. In addition, shift tables 
based on normal ranges and incidence rates of notable abnormalities (see Appendix 1) will be 
presented.
Pharmacokinetics
All completed subjects with quantifiable pharmacokinetic (PK) measurements of 
secukinumab will be included in the pharmacokinetic data anal ysis. Serum concentrations will 
be expressed in mass per volume units. All concentrations below the limit of quantification or 
missing data will be labeled as such in the concentration data listings. PK concentrations will 
be summarized by [CONTACT_3232]. In addition to mean, standard deviation, 
coefficient of variation, median and quartiles, the geometric mean and geometric coefficient 
of variation and n(log) will be presented.

[COMPANY_001] Confidential Page [ADDRESS_1135013] 80 patients.  Assuming approximately  70% to 85% 
of patients respond in Treatment Period 1, the estimated minimum number of patients treated 
in Treatment Period 1 is between 70 and 86. Under the assumption of 12 months of accrual 
duration, the total maximum expected study  duration is 33 months. The expected number of 
flare events is 12 and 21 respecti vely for secukinumab and placebo group in Treatment Period 
2.
10 Ethical considerations 
10.1 Regulatory  and ethical compliance 
This clinical study  was designed and shall be implemented, executed and reported in 
accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with 
applicable local regulations (including European Directive 2001/20/EC, US CFR 21, and 
Japanese Ministry  of Health, L abor, and Welfare), and with the ethical principles laid down in 
the Declaration of Helsinki.
10.2 Informed consent procedures
Eligible patients may only be included in the study  after providing written (witnessed, where 
required by [CONTACT_6617]), Institutional Review Board (IRB)/ Independent Ethics 
Committee (IEC)-approved informed consent, or, if incapable of doing so, after such consent 
has been provided by a legally  acceptable representative(s) of the patient. In cases where the 
patient’s representative gives consent, the patient must be informed about the study  to the 
extent possible given his/he r understanding. If the patient is capable of doing so, he/she must 
indicate assent by [CONTACT_233632] a 
separate assent form. Informed consent must be obtained before conducting any  study -specific 
procedures (e.g. all of the procedures described in the protocol). The process of obtaining 
informed consent must be documented in the patient source documents. 
[COMPANY_001] will provide to investigators in a separate document a proposed informed consent 
form that complies with the ICH GCP guideline and regulatory  requirements and is 
considered appropriate for this study . Any  changes to the proposed consent form suggested by  
[CONTACT_786982]/IEC, and a copy 
of the approved version must be provided to the [COMPANY_001] monitor after IRB/IEC approval.
In pediatric patients (< 18 years of age) parental permission and, whenever possible, child 
assent is needed instead of the procedure for informed consent used for research involving 
adults. In general, one or both parents or a guardian must be provided with the information 
ordinarily required for informed consent, so that they  may  decide whether to allow the child to 
participate, and children capable of assent must also express their willingness to participate. 
These forms will be submitted for IRB/IEC/REB approval.
Women of child bearing potential/guardian must be informed that taking the study  treatment 
may involve unknown risks to the fetus if pregnancy  were to oc cur during the study  and agree 
that in order to participate in the study  they must adhere to the contraception requirement for 
the duration of the study . If there is any  question that the patient will not reliably  comply , they 
must not be entered in the st udy.

[COMPANY_001] Confidential Page [ADDRESS_1135014] be approved by [CONTACT_5343], health authorities where required, and the IRB/IEC prior to 
implementation. Only  amendments that are intended to eliminate an apparent immediate 
hazard to patients may be implemented immediately  provided the health authorities are 
subsequently  notified by [CONTACT_6670]/IEC is notified. 
Notwithstanding the need for approval of formal protocol amendments, the Investigator is 
expected to take any immediate action requir ed for the safet y of any patient included in this 
study , even if this action represents a deviation from the protocol. In such cases, the reporting 
requirements identified in Section [ADDRESS_1135015] be followed.

[COMPANY_001] Confidential Page 89
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
12 References (available upon request)
Barba G, Buck C, Bammann K, et al (2014) Blood pressure reference values for European 
non-overweight school children: the IDEFI CS study . Int J Obes (Lond); [ADDRESS_1135016] 2:S48 - 56. 
Brunner H, Lovell D, Finck B et al (2002) Preliminary  definition of disease flare in juvenile 
rheumatoid arthritis. J Rheumatol ;29:1058-1064.
Beuckelman T, Patkar N, Saag K, et al (2011) American College of Rheumatology  
Recommendations for the Treatment of Juvenile Idiopathic Arth ritis: I nitiation and Safety  
Monitoring of Therapeutic Agents for the Treatment of Arthritis and Sy stemic Features. 
Arthritis Ca re & Research; Vol. 63 (4): 465
-482.
Consolaro A, Ruperto N, Bazso A, et al (2009) Development and validation of a composite 
dis
ease activity  score for juvenile idiopathic arthritis. Arthritis Rheum; 61(5):658-66.
Consolaro A, Bracciolini G, Ruperto N, et al. (2012) Remission, minimal disease activity , and 
acceptable s ymptom state in juvenile idiopathic arthritis: defining criteria
based on the 
juvenile arthritis disease activity  score. Arthritis Rheum. Jul;64(7):2366 -74. 
Cosenty x®(Secukinumab) label, 2016
EMA (2015). Guideline on clinical investigation of medicinal products for the treatment of 
juvenile idiopathic arthritis
Feld LG and Corey  H (2007) Hy pertension in childhood, Pediatric in Review 28: 283-98.
Horneff 2009, G. Horneff G and Burgos -Vargas R (2009) Juvenile idiopathic arthritis. 
Subgroup characteristics and comparisons between rheumatoid arthritis -like subgroups and 
ankylosing spondy
litis-like subgroups.  Clin Exp Rheumatol; 27 (Suppl. 55): S131 - 138.
Lovell DJ, G iannini EH, R EIFFA, et al (2000)  Etanercept in Children w ith Poly articular 
Juvenile Rheumatoid Arthritis . The New England Journal of Medicine 2000; volume 342 (11) 
763-69
Lovell DJ, Ruperto N, Giannini EH, et al (2013) Advances from clinical trials in juvenile 
idiopathic arthritis. 
Nat Rev Rheumatol 2013; 9: 557 –563.
Magni -Manzoni S, Rossi F, Pi[INVESTIGATOR_40963] A et al. (2003) Prognostic factors for radiographic 
progression, radiographic damage, and disabilit y in juvenile idiopathic arthritis. Arthritis
Rheum. 2003 Dec;48(12):3509 -17.
Martini (2003) Are the Number of Joints I nvolved or the Presence of Psoriasis Still Useful 
Tools to I dentify  Homogeneous Disease Entities in Juvenile I diopathic Arthritis? J 
Rheumatol;30;1900 -1903.
Martini A. (2012) It is time to rethink juvenile idiopathic arthritis classification and 
nomenclature Ann Rheum Dis;71:1437–1439.
Petty  RE, Southwood TR, Manners P, et al (2004) International League of Associations for 
Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 
2001; J Rheumatol. 2004 Feb;31(2):390 -2.

[COMPANY_001] Confidential Page 91
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
13 Appendix 1: Clinically  notable laboratory  values and vital 
signs
The following defined notable laboratory  or vital sign abnormalities, except creatinine 
clearance, will be communicated at the same time as they  are sent to investigators to [COMPANY_001].  
[COMPANY_001] will determine if further consultations with I nvestigator(s) are appropriate.
Labora tory Criteria
Newl y occurring selected notable laboratory  abnormalities in pediatric patients at the time of 
the assessment:
Biochemistry
Alanine aminotransferase (ALT)(SGPT): 
> Upper Limit of Normal (ULN)
≥3 x UL N
≥5 x UL N
≥8 x UL N
≥10 x UL N
Aspartate aminotransferase (AST) (SGOT): 
>ULN
≥3 x UL N
≥5 x UL N
≥8 x UL N
≥10 x UL N
Total Bilirubin (TBL)
>ULN, 
≥1.5xUL N, 
≥ 2xUL N
ALP 
>ULN
≥1.5xUL N, 
≥2xUL N, 
≥3x UL N 
≥5xUL N
ALT and/or AST >3x- , 5x-, 10x UL N accompanied by  [CONTACT_121988] >2xULN
ALT or AST >3x ULN and TBL >2x -, and ALP >[ADDRESS_1135017].
ALP >3x ULN and TBL >2x UL N

[COMPANY_001] Confidential Page 92
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
Gamma -Glutam yltransferase (GGT): 
>ULN
≥3 x UL N
≥5 x UL N
Creatinine (serum): ≥1.[ADDRESS_1135018]
Creatinine clearance (Schwartz formula§): ≥ 25% decrease from baseline, ≥3 months in 
duration
Protein urine dipstick: 
New protein ≥1+, ≥3 months in duration
Creatinine clearance (Schwartz formula§): ≥ 25% decrease from baseline, ≥3 months in 
duration in combination with protein urine dipstick resulting in new protein ≥1+, ≥3 
months in duration
Total Cholestero l: ≥1.5xULN
Trigl ycerides: ≥5.7 mmol/L .
§Schwartz formula -Creatinine clearance (mL/min/1.73m2)  was derived using the following 
formula 0.413 x length (cm) / (serum creatinine (mg/dL) ( Schwartz et al 2009 ).
For creatinine clearance only, baseline value for the decrease from baseline criterion will be 
calculated as the average of all values prior to the first dose (i.e. screening and baseline 
values).
Hematology
Hemoglobin: ≥ 20 g/L decrease from baseline, 
or < 85 g/L for < 16 years of age
< 100 g/L for ≥ 16 y ears of age
Absolute neutrophils:
Grade 1: <LLN – 1.5 x 10E9/L
Grade 2: <1.5 – 1.0 x 10E9/L
Grade 3: <1.0 – 0.5 x 10E9/L
Grade 4: <0.5 x 10E9/L
Criteria based on CTC grades for platelet count:
Grade 1: <LLN – 75.0 x 10E9/L
Grade 2: <75.0 – 50.0 x 10E9/L
Grade 3: <50.0 – 25.0 x 10E9/L
Grade 4: <25.0 x 10E9/L
Criteria based on CTC grades for WBC:
Grade 1:<LLN – 3.0 x10E9/L
Grade 2:<3.0 –2.0 x10E9/L
Grade 3:<2.0 –1.0 x10E9/L
Grade 4: <1.0 x10E9/L
Absolute Ly mpho cytes: < LLN 

[COMPANY_001] Confidential Page 93
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
Absolute Eosinophils: ≥ 1.[ADDRESS_1135019]
Absolute Eosinophils: ≥0.45 x 109/L  
Vital Signs
The following criteria will be used.
Note : The age is the age at the time of the visit. 
Systolic blood pressure (mmHg):
High: >ULN and Increased >20 in change from baseline
Diastolic blood pressure (mmHg):
High: >ULN and Increased >20 in change from baseline
Pulse (bpm)§: 
High: >ULN and Increased >20 in change from baseline
Low: <LLN and Decreased >20 in change from baseline
Note :Only post -baseline values wil l be flagged as notable abnormalities
Table 13-1 Reference ranges for systolic and diastolic blood pressures and pulse.
Age Systolic Blood 
Pressure lower and 
upper limits
(mmHg)Diastolic Blood 
pressure lower and 
upper limits
(mmHg)Pulse lower and 
upper limits
(Beats per minute)
2 yrs 84-117 39-72 90-150
3 yrs 86-120 44-76 90-150
4 yrs 88-122 47-79 90-150
5 yrs 89-123 50-82 65-135
6 yrs 91-125 53-84 65-135
7 yrs 92-126 55-86 60-130
8 yrs 94-127 56-88 60-130
9 yrs 95-129 57-89 60-130
10 yrs 97-130 58-90 60-110
11 yrs 99-132 59-90 60-110
12 yrs 101-135 59-91 60-110
13 yrs 104-137 60-91 60-110
14 yrs 106-140 60-92 60-110
15 yrs 107-142 61-93 60-110
16 yrs 108-145 63-94 60-110
17 yrs 108-147 64-97 60-110
18 yrs 108-147 64-97 60-100

[COMPANY_001] Confidential Page 94
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
Table 13-2 Recommended dimensions for blood pressure cuff bladders
Width [cm] Length [cm] Maximum A rm 
Circumference 
[cm]*
Newborn 4 8 10
Infant 6 12 15
Child 9 18 22
Small adult 10 24 26
Adult 13 30 34
Large adult 16 38 44
*calculated so that the bladder can encircle even the largest arm by  [CONTACT_2669] 80%
Source: Feld LG and Corey  H (2007) : Hypertension in childhood, Pediatric in Review 28: 
283-98

[COMPANY_001] Confidential Page 95
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
14 Appendix 2: Liver event and Laborator y trigger Definitions 
and Follo w-up Requirements
Table 14-1 Liver Event and Laboratory  Trigger Definitions
Definition/threshold
LIVER LABORATORY TRIGGERS [ADDRESS_1135020] < ALT / AST [ADDRESS_1135021]
1.[ADDRESS_1135022] < TBL [ADDRESS_1135023]
LIVER EVENTS ALT or AST > 5 × ULN
ALP > 2 × ULN (in the absence of known bone pathology)
TBL > 2 × ULN (in the absence of known Gilbert 
syndrome)
ALT or AST > 3 × ULN and INR > 1.5
Potential Hy’s Law cases (defined as ALT or AST > 3 × 
ULN and TBL > 2 × ULN [mainly conjugated fraction] 
without notable incr ease in ALP to > 2 × ULN)
Any clinical event of jaundice (or equivalent term)
ALT or AST > 3 × ULN accompanied by (general) 
malaise, fatigue, abdominal pain, nausea, or 
vomiting, or rash with eosinophilia
Any adverse event potentially indicative of a liver 
toxicity *
Table 14-2 Follo w Up Requirements for Liver Events and Laboratory  Triggers
Criteria Actions required Follow -up monitoring
Potential Hy’s Law 
caseaDiscontinue the study drug 
immediately
Hospi[INVESTIGATOR_18552], if clinically appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and GGT until resolutionc(frequency 
at Investigator discretion)
ALT or AST
> 8 × ULN Discontinue the study  drug 
immediately
Hospi[INVESTIGATOR_18553]
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at Investigator discretion)
> 3 × ULN and 
INR > 1.5Discontinue the study drug 
immediately
Hospi[INVESTIGATOR_18552], if clinically appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at Investigator discretion)
> 5 to ≤ 8 × ULN Repeat LFT within 48 hours
If elevation persists, continue follow -ALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 

[COMPANY_001] Confidential Page 96
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
Criteria Actions required Follow -up monitoring
up monitoring
If elevation persists for more than 2 
weeks , discontinue the study drug
Establish causality
Complete liver CRFat Investigator discretion)
> 3 ×ULN 
accompa nied by 
[CONTACT_18688]Discontinue the study drug 
immediately
Hospi[INVESTIGATOR_18553]
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at Investigator discretion)
> 3 to ≤ 5 × ULN 
(patient is 
asymptomatic)Repeat LFT within the next week
If elevation is confirmed, initiate close 
observation of the patientInvestigator discretion
Monitor LFT within 1 to 4 weeks 
ALP (isolated)
> 2 ×ULN (in the 
absence of known 
bone pathology)Repeat LFT within 48 hours
If elevation persists, establish 
causality
Complete liver CRFInvestigator discretion
Monitor LFT within 1 to 4 weeks or 
at next visit
TBL (isolated)
> 2 × ULN (in the 
absence of known 
Gilbert syndrome)Repeat LFT within 48 hours
If elevation persists, discontinue the 
study drug immediately
Hospi[INVESTIGATOR_18553]
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at Investigator discretion)
Test for hemolysis (e.g., 
reticulocytes, haptoglobin, 
unconjugated [indirect] bilirubin)
> 1.5 to ≤ 2 × ULN
(patient is 
asymptomatic)Repeat LFT within the next week
If elevation is confirmed, initiate close 
observation of the patientInvestigator discretion
Monitor LFT within 1 to 4 weeks or 
at next visit
Jaundice Discontinue the study drug 
immediately
Hospi[INVESTIGATOR_18554]
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at Investigator discretion)

[COMPANY_001] Confidential Page 97
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
Criteria Actions required Follow -up monitoring
Any AE potentially 
indicative of a liver 
toxicity*Consider study drug interruption or 
discontinuation 
Hospi[INVESTIGATOR_6549]
Establish causality
Complete liver CRFInvestigator discretion
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage -
related conditions; the non -infectious hepatitis; the benign, malignant and unspecified liver neoplasms
aElevated ALT/AST > 3 × ULN and TBL > 2 × ULN but without notable increase in ALP to > 2 × ULN
b(General) malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia 
cResolution is defined as an outcome of one of the following: (1) return to baseline values, (2) stable 
values at three subsequent monitoring visits at least 2 week s apart, (3) remain at elevated level after a 
maximum of 6 months, (4) liver transplantation, and (5) death.

[COMPANY_001] Confidential Page 98
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
15 Appendix 3: Specific Renal A lert Criteria and A ctions
Table 15-1 Specific Renal A lert Criteria and A ctions
Serum Event
Serum creatinine increase
25 –49% compared to baseline and is above 
ULNConfirm 25% increase after 24- 48h 
Follow up within 2 -5 days
Acute Kidney Injury: Serum creatinine increase 
50% compared to baseline and is above the 
ULNFollow up within 24 -48h if possible
Consider study treatment interruption 
Consider patient hospi[INVESTIGATOR_059] /specialized 
treatment
Urine Event
New dipstick proteinuria ≥1+
Albumin -or Protein -creatinine ratio increase ≥ 
2-fold
Albumin -creatinine ratio (ACR) ≥ 30 mg/g or ≥ 3 
mg/mmol;
Protein -creatinine ratio (PCR ) ≥ 150 mg/g or > 
15 mg/mmolConfirm value after 24- 48h
Perform urine microscopy
Consider study treatment interruption / or 
discontinuation 
New dipstick glycosuria ≥ 1+ not due to diabetes Blood glucose (fasting)
Perform serum creatinine, ACR 
New dipstick hematuria ≥ 1+ not due to trauma Urine sediment microscopy
Perform serum creatinine, ACR 
For all renal events:
Document contributing factors in the CRF : co-medication, other co -morbid conditions, and additional 
diagnostic procedures performed 
Monitor patient regularly (frequency at investigator’s discretion) until either: 
Event resolution: sCr within 10% of baseline or protein -creatin ine ratio within 50% of baseline, or
Event stabilization: sCr level with ±10% variability over last 6 months or protein -creatinine ratio 
stabilization at a new level with ± 50% variability over last 6 months.

[COMPANY_001] Confidential Page 99
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
16 Appendix 4: Weight ranges: recommended maximum
sample blood volume per blood draw 
Recommended maximum blood collections are in accordance with the 2008 EU Commission 
Guideline on Ethical Considerations for Clinical Trials on Medicinal Products Conducted 
with the Pediatric Population.  As per the guideline, collections specified in the protocol do 
not exceed 3% of patients’ total blood volume during a 4 -week period and/or 1% at an y single 
visit.  Patients’ total blood volume is estimated at 80 to 90 mL /kg bod y weight; 3% is 2.4 mL  
blood per kg bod y wei ght, 1% is 0.8 mL  blood per kg body weight.  The table below outlines 
the maximum allowable blood volume by  [CONTACT_786983] .  In order to stay within these limits, 
detailed instructions are provided b y the Central Laboratory for all weight categories less than 
38 kg.  
Table 16-1 Weight range: Recommended maximum blood volume dra wn per visit, 
and per 4 week period
Weight Range 
Category (kg)Maximum A llowable Blood 
Volume Drawn / visit
(mL)Maximum A llowable Blood 
Volume Drawn / 4 week period 
(mL)
7-10 5.6 16.8
>10-12 8.0 24.0
>12-14 9.6 28.8
>14-26 11.2 33.6
>26-38 20.8 62.4
>38 30.4 91.2
17 Appendix 5: Phy sician’s global assessment of disease 
activity  (VAS)
The question text below will be shown to and will be answered b y the ph ysician.  The 
physician’s assessment should be made and recorded without viewing ANY of the patient’s 
assessments. The result of the phy sician’s assessment of the patient’s disease activity  should 
be withheld from the patient / parents/guardian so as not to influence his/her own assessment.
The following is the text of the question, but does not represent the final formatting used in the 
study.
“Considering all the ways ERA/JPsA affects your patient, how would you rate his or her 
condition today ?”
No disease activity 
0Very severe disease activity 
100

[COMPANY_001] Confidential Page 100
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
18 Appendix 6: Childhood Health A ssessment Questionnaire 
(CHA Q)
The following does not represent the final formatting of the CHAQ used in the study .

[COMPANY_001] Confidential Page 101
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304

[COMPANY_001] Confidential Page 102
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
19 Appendix 7: ILA R classification criteria
Criteria Exclusions
JPsA (M ODIFIED) Arthritis and psoriasis, or
arthritis with two or more of:
(a)Dactylitis
(b)Nail pi[INVESTIGATOR_786936]
(c)Psoriasis in a first degree 
relativePresence of IgM RF on 
at least [ADDRESS_1135024] 3 months apart
Presence of sy stemic 
JIA
ERA Arthritis and enthesitis, or 
Arthritis or enthesitis with two or 
more of:
(a) Presence of or histor y of 
sacroiliac joint tenderness 
and/or inflammatory 
lumbosacral pain 
(b)HLA-B27 positivity
(c)Acute (symptomatic ) anterior
uveitis
(d)History of ank ylosing 
spondylitis, enthesitis related 
arthritis, sacroiliitis with 
inflammatory  bowel disease, 
Reiter’s syndrome, or ac ute 
anterior uveitis in a first -
degree relative
(e)Onset of arthritis in a boy 
over the age of 6 yearsPsoriasis or in first -
degree relative
Presence of IgM RF on 
at least 2 occasions 
more than 3 months 
apart
Presence of sy stemic 
JIA 
JPsA criteria ( Petty et al 2004 ) have been modified by [CONTACT_786985] 2 exclusions:   1)
Arthritis in a HLA-B27 positiv emale beginning after the 6thbirthday and 2) diagnosis of ank ylosing 
spondylitis, ERA, sacroiliitis with Inflammatory  Bowel Disease (IBD), reactive arthritis (Reiter’s 
syndrome) , or acute anterior uveitis, or a histor y of one of these disorders in a first -degree relative.

[COMPANY_001] Confidential Page 103
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
20 Appendix 8: A CR definition of flare for JIA  
Both criteria [ADDRESS_1135025] be fulfilled to meet the definition of a disease flare.  Criteria 
changes described are relative to the End of Treatment Period 1 (Week 12 visit).
1.≥ 30% worsening in at least 3 of the 6 ACR response variables 
Physician global assessment of overall disease activit y 
Parent or patient global assessment of overall well -being 
Functional ability  (CHAQ©) 
Number of joints with active arthritis
Number of joints with limited range of motion 
Index of inflammation: CRP
2.≥ 30% improvement in no more than 1 of the 6 ACR response variables 
Contingencies:
if the Phy sician or Parent Global Assessment is one of the 3 response variables used to 
define flare, worsening of ≥ 20 mm (1 - 100mm visual analogue scale) must be present;
if the number of active joints or joints with limitation of motion is one of the 3 response 
variables used to define flare, worsening in ≥  [ADDRESS_1135026] be present;
if CRP is one of the [ADDRESS_1135027] be above normal range.

[COMPANY_001] Confidential Page 104
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
21 Appendix 9: A CR response criteria
The adapted ACR Pediatric 30/50/70/90/[ADDRESS_1135028] 30/50/70/90/100% respectively inatleast 3
of
6components with no more than one component worsening more than 30% as defined in 
the ACR criteria.
The components are:
Physician’s Global Assessment of disease activity  on a 0 -100 mm VAS from 0 mm = no 
disease activity  to 100 mm = very  severe disease activity .
Parent’s or patient’s (if ap propriate in age) Global Assessment of Subject’s overall well -
being on a 0- 100 mm VAS from 0 mm= very  well to 100 mm= very  poor.
Functional ability : Childhood Health Assessment Questionnaire (CHAQ©)
Number of joints with active arthritis using the ACR definition (The ACR definition of 
active arthritis is any  joint with swelling, or in the absence of swelling, limitation of 
motion accompanied b y either pain on motion or tenderness not due to deformity )
Number of joints with limitation of motion
Laboratory  measure of inflammation: CRP (mg/L )

[COMPANY_001] Confidential Page 105
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
22 Appendix 10: Criteria for de ﬁning clinical inactive disease
Criteria for de ﬁning clinical inactive disease in ERA /JPsA
Inactive disease: 
No joints with active arthritis
CRP level within normal limits in the laboratory where tested or, if elevated, not 
attributable to ERA/ JPsA
Physician’s global assessment of disease activity score of best possible on the scale 
used (i.e. best possible score is defined as 10 mm )
The absence of patient -reported morning stiffness attributable to JPsA or ERA lasting 
≥15 minutes 
No Uveitis
Adapted from Wallace CA, et al (2011) . 

[COMPANY_001] Confidential Page 106
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304

[COMPANY_001] Confidential Page 107
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304

[COMPANY_001] Confidential Page 108
Amended Protocol Version v02 Clean Protocol No. CAIN457F2304
